[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 793
1. Sokolic RA, Bauer TR, Gu YC, Hai M, Tuschong LM, Burkholder T, Colenda L, Bacher J, Starost MF, Hickstein DD: Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency. Biol Blood Marrow Transplant; 2005 Oct;11(10):755-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukocyte adhesion deficiency (LAD)-1, a primary immunodeficiency disease caused by molecular defects in the leukocyte integrin CD18 molecule, is characterized by recurrent, life-threatening bacterial infections.
  • Myeloablative hematopoietic stem cell transplantation is the only curative treatment for LAD-1.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 1999;5(5):316-21 [10534062.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1261-3 [10642820.001]
  • [Cites] J Small Anim Pract. 2000 May;41(5):211-7 [10907223.001]
  • [Cites] Transplantation. 2001 Feb 15;71(3):433-9 [11233907.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(3):145-54 [11939604.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):477-85 [12374452.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):493-500 [12374454.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):979-81 [12476295.001]
  • [Cites] Leukemia. 2003 Mar;17(3):613-20 [12646952.001]
  • [Cites] Leuk Lymphoma. 2003 Apr;44(4):669-79 [12769345.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jun;9(6):373-82 [12813445.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Jul 15;94(1-2):11-22 [12842608.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Oct 15;95(3-4):113-21 [12963272.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Nov;9(11):722-4 [14682302.001]
  • [Cites] Pediatr Res. 2004 Mar;55(3):363-7 [14711903.001]
  • [Cites] Blood. 2004 May 1;103(9):3582-9 [14715622.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1696-705 [15117992.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1273-80 [15126320.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Nov;10(11):805-12 [15505611.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):443-7 [1089620.001]
  • [Cites] Drug Metab Dispos. 1980 Mar-Apr;8(2):60-3 [6103788.001]
  • [Cites] J Exp Med. 1984 Dec 1;160(6):1901-18 [6096477.001]
  • [Cites] J Infect Dis. 1985 Oct;152(4):668-89 [3900232.001]
  • [Cites] Annu Rev Med. 1987;38:175-94 [3555290.001]
  • [Cites] Cell. 1987 Jul 17;50(2):193-202 [3594570.001]
  • [Cites] Blood. 1989 Jul;74(1):512-6 [2665844.001]
  • [Cites] Lab Anim Sci. 1990 Jan;40(1):11-5 [2153851.001]
  • [Cites] Vet Immunol Immunopathol. 1993 Dec;39(4):461-6 [8116221.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1629-35 [7632973.001]
  • [Cites] Transplantation. 1996 Sep 27;62(6):876-7 [8824495.001]
  • [Cites] Bone Marrow Transplant. 1996 Oct;18(4):767-76 [8899193.001]
  • [Cites] Transplantation. 1999 Aug 15;68(3):338-44 [10459536.001]
  • [Cites] Biol Blood Marrow Transplant. 1999;5(4):192-203 [10465099.001]
  • [Cites] Genomics. 1999 Oct 1;61(1):101-7 [10512685.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(1):17-23 [15502853.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1010-5 [15383461.001]
  • [Cites] Exp Hematol. 2005 Jun;33(6):706-12 [15911095.001]
  • (PMID = 16182176.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC010384-05; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; G1LN9045DK / Busulfan; HU9DX48N0T / Mycophenolic Acid
  • [Other-IDs] NLM/ NIHMS7147; NLM/ PMC1351378
  •  go-up   go-down


2. Han Y, Xue Y, Zhang J, Wu Y, Pan J, Wang Y, Shen J, Dai H, Bai S: Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2008 Dec;187(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Translocation (14;14)(q11;q32) is one of the recurrent chromosome aberrations in ataxia-teleangiectasia (AT) and T-cell malignancies.
  • Fluorescence in situ hybridization (FISH) demonstrated trisomy 4 and the simultaneous involvement of the IGH gene at 14q32 and the CEBPE gene at 14q11, which differs from the genes involved in T-cell leukemias.
  • Later, she received allogeneic peripheral blood stem cell transplantation.
  • We suggest that t(14;14)(q11;q32) involving the IGH and CEBPE genes in B-ALL is rare, but it is a recurrent abnormality that could identify a new subgroup of B-ALL.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Chromosomes, Human, Pair 14 / genetics. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027493.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 142805-41-2 / CEBPE protein, human; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; VDP protocol
  •  go-up   go-down


3. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martín-Subero JI, Nieländer I, Garcia-Conde J, Dyer MJ, Terol MJ, Pinkel D, Martinez-Climent JA: Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood; 2005 Jun 1;105(11):4445-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
  • To identify recurrent genomic changes in mantle cell lymphoma (MCL), we used high-resolution comparative genomic hybridization (CGH) to bacterial artificial chromosome (BAC) microarrays in 68 patients and 9 MCL-derived cell lines.
  • Array CGH defined an MCL genomic signature distinct from other B-cell lymphomas, including deletions of 1p21 and 11q22.3-ATM gene with coincident 10p12-BMI1 gene amplification and 10p14 deletion, along with a previously unidentified loss within 9q21-q22.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia / genetics. Lymphoma, Mantle-Cell / genetics


Advertisement
4. Dorrepaal SJ, Margolin EA, Wang C: Bilateral pseudohypopyon as a presenting feature of recurrent diffuse large B-cell lymphoma. J Neuroophthalmol; 2010 Mar;30(1):67-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral pseudohypopyon as a presenting feature of recurrent diffuse large B-cell lymphoma.
  • A 55-year-old man with Gaucher disease and B-cell lymphoma developed a white meniscus along the inferior portion of the anterior chamber of both eyes.
  • Aspiration of aqueous fluid confirmed that the meniscus was made up of lymphoma cells, indicating that it was a pseudohypopyon. (A true hypopyon is made up of reactive white blood cells.
  • This is the first report of binocular pseudohypopyon confirmed as lymphomatous by flow cytometric immunophenotyping analysis in a patient with diffuse large B-cell lymphoma.
  • [MeSH-major] Anterior Chamber / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182212.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Chu PG, Loera S, Huang Q, Weiss LM: Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. Am J Clin Pathol; 2006 Oct;126(4):534-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
  • We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20- recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20- diffuse large B cell lymphoma (DLBCL).
  • The percentages of cases expressing Pax-5, CD79a, OCT.2, and BOB.1 in CD20- recurrent mature B-cell lymphomas after rituximab treatment were 88% (21/24), 84% (21/25), 81% (17/21), and 73% (16/22), respectively.
  • CD79a and Pax-5 should be used as the first-line B lineage-specific markers for rituximab-treated CD20- mature B-cell lymphomas.
  • [MeSH-major] Antigens, CD20 / analysis. B-Lymphocytes / pathology. Burkitt Lymphoma / pathology. Cell Lineage. Immunohistochemistry / methods. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938666.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


6. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer; 2006 Jan 1;106(1):120-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
  • BACKGROUND: Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30% and a median survival ranging from 2-6 months.
  • METHODS: A Phase II clinical trial of single-agent SV given at a dose of 2.0 mg/m2 every 2 weeks was conducted in patients with recurrent or refractory ALL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [ErratumIn] Cancer. 2006 Apr 1;106(7):1641
  • (PMID = 16331634.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 0 / Sphingomyelins; 5J49Q6B70F / Vincristine
  •  go-up   go-down


7. MacDonald DH, Clark I, Naresh KN: The Hammersmith Hospital hematopathology case of the month: paraspinal B lymphoblastic lymphoma – problems in diagnosis and initial indolent behavior. Leuk Lymphoma; 2010 Oct;51(10):1913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Hammersmith Hospital hematopathology case of the month: paraspinal B lymphoblastic lymphoma – problems in diagnosis and initial indolent behavior.
  • Biopsy showed features of a small B-cell lymphoma possibly of follicle center cell origin.
  • Biopsy of the recurrent lesion showed features of B lymphoblastic leukemia/lymphoma.
  • [MeSH-major] Leukemic Infiltration / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Thoracic Vertebrae / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858095.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


8. Yoshida Y, Toma Y, Arai M, Higashi R, Kashihara K, Kaizaki Y: [Primitive neuroectodermal tumor arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia: case report]. No Shinkei Geka; 2005 Jul;33(7):717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follow-up MRI showed no evidence of recurrent tumor 4 months after the radiotherapy.
  • [MeSH-major] Brain Neoplasms / surgery. Cranial Irradiation. Neoplasms, Second Primary. Neuroectodermal Tumors, Primitive / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001813.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Higuchi M, Muta T, Karube KN, Eto T, Yamano Y, Ohshima K: Epstein-Barr virus-positive blastoid variant of mantle cell lymphoma in an adult with recurrent infectious mononucleosis-like symptoms: a case report. Int J Hematol; 2007 Apr;85(3):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive blastoid variant of mantle cell lymphoma in an adult with recurrent infectious mononucleosis-like symptoms: a case report.
  • Epstein-Barr virus (EBV) is closely associated with several lymphomas, such as Burkitt lymphoma, natural killer/T-cell lymphoma, peripheral T-cell lymphoma, and Hodgkin's lymphoma; however, whether EBV is implicated in mantle cell lymphoma (MCL) has not been established.
  • We report the case of an adult with recurrent infectious mononucleosis (IM)-like symptoms who developed an EBV-positive blastoid variant of MCL.
  • He had a history of recurrent IM-like symptoms (prolonged fever and cervical lymphadenopathy) for at least 1 year.
  • EBV was detected in most of the lymphoma cells and in the peripheral blood.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Infectious Mononucleosis / virology. Lymph Nodes / pathology. Lymphoma, Mantle-Cell / virology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):569-78 [11568749.001]
  • [Cites] Int J Hematol. 1998 Feb;67(2):165-74 [9631583.001]
  • [Cites] Blood. 2001 Jul 15;98(2):280-6 [11435294.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] Intern Med. 2004 Oct;43(10):986-9 [15575253.001]
  • [Cites] J Virol. 1996 Dec;70(12):9003-7 [8971032.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):24-31 [12894847.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):259-62 [10846832.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Intern Med. 2005 Oct;44(10):1097-9 [16293926.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):194-9 [12827658.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3803-9 [9850025.001]
  • (PMID = 17483058.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Torlakovic EE, Aamot HV, Heim S: A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma. J Pathol; 2006 Jun;209(2):258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma.
  • Marginal zone differentiation of follicular lymphomas (FL), sometimes referred to as monocytoid B-cell differentiation, is a relatively uncommon phenomenon.
  • We have analysed 131 primary nodal FL with t(14;18)(q32;q21) for secondary cytogenetic aberrations previously described as recurrent in marginal zone lymphomas (MZL) to identify their frequency and possible association with morphological evidence of marginal zone differentiation.
  • None of the recurrent balanced translocations characteristic of extranodal MZL were seen secondarily in the nodal FLs with t(14;18)(q32;q21).
  • However, 43/131 (33%) cases had at least one of the above secondary cytogenetic aberrations previously reported as recurrent aberrations in MZL and, when combined, these were significantly more frequent in FL with morphological evidence of marginal zone differentiation (p<0.0001, two-sided Fisher's exact test).
  • Aberrations of chromosome 3 and, in particular, trisomy 3 occurred frequently in FL with marginal zone differentiation (p=0.002 and p<0.0001, respectively, two-sided Fisher's exact test), while chromosome 21, 22, and X chromosome aberrations, which have not been described previously as recurrent in MZL, were also significantly associated with marginal zone differentiation in FL (p=0.002, p=0.037, p=0.039, respectively, two-sided Fisher's exact test).
  • [MeSH-major] Chromosome Aberrations. Lymphoma, Follicular / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Cell Differentiation / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 7 / genetics. Cytogenetic Analysis / methods. Humans. Immunophenotyping / methods. Phenotype. Trisomy / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16583359.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Jogai S, Al-Jassar A, Dey P, Adesina AO, Amanguno HG, Francis IM: Fine needle aspiration cytology of Hodgkin's lymphoma: A cytohistologic correlation study from a cancer center in Kuwait. Acta Cytol; 2006 Nov-Dec;50(6):656-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of Hodgkin's lymphoma: A cytohistologic correlation study from a cancer center in Kuwait.
  • OBJECTIVE: To assess the diagnostic accuracy offine needle aspiration cytology (FNAC) in the diagnosis of Hodgkin's lymphoma (HL).
  • Of these, 42 were correctly diagnosed as HL, and there was a discorrelation in 4 cases, comprising 3 cases of non-HL (T-cell-rich B-cell lymphoma [TCRBCL]-2, anaplastic large cell lymphoma-1) and 1 case of metastatic carcinoma.
  • CONCLUSION: FNAC is very useful for rapid and accurate approach to the diagnosis of recurrent and most cases of primary HL.
  • Because of morphologic similarities, it is difficult to differentiate HL from anaplastic large cell lymphoma and TCRBCL on FNAC.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Cancer Care Facilities. Child. Child, Preschool. Diagnosis, Differential. Diagnostic Errors. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kuwait. Lymphoma, B-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Male. Middle Aged. Reproducibility of Results. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol; 2006 Nov;85(11):787-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
  • Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin's lymphoma (NHL) of childhood.
  • Despite these improvements, the outcome for children with recurrent or refractory NHL remains dismal.
  • We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT.
  • All patients had refractory or recurrent NHL.
  • Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt's, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored.
  • In regard to the patients, six had Burkitt's lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma.
  • The EFS for Burkitt's, lymphoblastic, and large-cell lymphoma was 66.7+/-27.2, 50.5+/-14.8, and 82.1+/-11.7%, respectively.
  • In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P = 0.037).
  • EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6+/-24.9%, respectively (P = 0.106).
  • Status at transplantation was the most predictive factor for the survival after HDC/PBSCT (EFS for CR 70.8+/-9.5% vs non-CR 20.0+/-17.9%, P = 0.008).
  • HDC/PBSCT is considered applicable to recurrent or refractory pediatric NHL patients safely and it could replace conventional chemotherapy.
  • However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Apr;86(4):309
  • (PMID = 16932891.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Kojima M, Morita Y, Nakamura N, Shimizu K, Murayama K, Nakamura S: Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases. Pathol Res Pract; 2008;204(4):267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Age-related Epstein-Barr virus (EBV)+B-cell lymphoproliferative disorder (LPD) is a recently recognized entity that occurs in patients over 40 years of age without any known immunodeficiency.
  • Histologically, age-related EBV+B-cell LPDs are classified into the polymorphous subtype and large B-cell lymphoma subtypes.
  • However, plasmacytic hyperplasia, which is thought to be the earliest recognizable EBV+PT-LPD, has not been reported among EBV+B-cell LPDs.
  • Pathologically, the initial lymph node biopsy specimens from both cases showed the classical Hodgkin lymphoma-like polymorphous subtype.
  • Hodgkin (H) and Reed-Sternberg (RS) cells were CD3-, CD20+, CD15-.
  • Repeated lymph node biopsy specimens from each case contained a mixture of lymphoid cells with prominent plasma cell differentiation, including immunoblasts without atypia.
  • As assessed by polymerase chain reaction (PCR) assay, only the initial biopsy specimen in Case 1 displayed a solitary faint immunoglobulin heavy chain (IgH) gene rearrangement, consistent with the presence of a small clonal B-cell population.
  • However, PCR analyses for EBV-genomes demonstrated the same single clonal infection of EBV in the initial and recurrent lymph node lesions in the present two cases.
  • These two cases demonstrated the presence of plasmacytic hyperplasia in age-related EBV+B-cell LPDs, and plasmacytic hyperplasia also appears to be the earliest lesion of age-related EBV+B-cell LPDs.
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Agents / therapeutic use. DNA, Viral / blood. Fatal Outcome. Flow Cytometry. Genes, Immunoglobulin Heavy Chain. Herpesvirus 4, Human / genetics. Hodgkin Disease / therapy. Hodgkin Disease / virology. Humans. Hyperplasia. Immunohistochemistry. In Situ Hybridization. Male. Polymerase Chain Reaction. RNA, Viral / analysis. Radiotherapy. Recurrence. Reed-Sternberg Cells / pathology. Reed-Sternberg Cells / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187262.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


14. Stevens WT, Bolan CD, Oblitas JM, Stroncek DF, Bennett JE, Leitman SF: Streptococcus agalactiae sepsis after transfusion of a plateletpheresis concentrate: benefit of donor evaluation. Transfusion; 2006 Apr;46(4):649-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen months after surgical resection and adjuvant chemotherapy, the donor had no evidence of recurrent tumor.
  • [MeSH-major] Plateletpheresis / adverse effects. Sepsis / etiology. Stem Cell Transplantation / adverse effects. Streptococcal Infections / etiology. Streptococcus agalactiae
  • [MeSH-minor] Aged. Blood Donors. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Female. Humans. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Transplantation, Homologous / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Sepsis.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584443.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wildes TM, Bartlett NL: Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk Lymphoma; 2009 Apr;50(4):529-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug development for recurrent and refractory classical Hodgkin lymphoma.
  • Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy.
  • High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse.
  • Targeted therapies for relapsed Hodgkin lymphoma include monoclonal antibodies directed at cell surface antigens, immunoconjugates, bispecific constructs created to recruit host effector cells and radioimmunotherapy.
  • In Epstein-Barr virus (EBV)-associated Hodgkin lymphoma, cytotoxic T lymphocytes directed at EBV antigens have been utilised in clinical trials with some success.
  • Additionally, the immunomodulatory agents thalidomide and lenalidomide, and new classes of drugs such as the mammalian target of rapamycin inhibitors and histone deacetylase inhibitors hold promise in relapsed Hodgkin lymphoma.
  • [MeSH-major] Drug Therapy / methods. Hodgkin Disease / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373650.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoconjugates; 0 / Immunotoxins
  • [Number-of-references] 84
  •  go-up   go-down


16. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W, Gynecologic Oncology Group: A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol; 2009 Nov;115(2):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
  • PATIENTS AND METHODS: Eligible women with recurrent EOC/PPC progressing between 6 and 12 months after initial chemotherapy were treated with bortezomib on days 1, 4, 8, and 11 [1.5 (cohort I) and 1.3 (cohort II) mg/m(2)/dose].
  • The 1.3 mg/m(2)/dose regimen is currently approved as an indication for multiple myeloma and mantle cell lymphoma.
  • CONCLUSION: Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712963.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA27469
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


17. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S: Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer; 2006 Jun 15;106(12):2645-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic leukemia and other CD52-positive lymphoproliferative disorders.
  • METHODS: Fifteen patients with CD52-positive (> or = 20%), recurrent or refractory acute leukemia (9 patients with AML and 6 patients with ALL) received alemtuzumab at a dose of 30 mg intravenously given 3 times a week (dose escalation during Week 1) for a total of 4 to 12 weeks.
  • CONCLUSIONS: Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688777.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


18. Sandler ES, Homans A, Mandell L, Amylon M, Wall DA, Devidas M, Buchanan GR, Lipton JM, Billett AL: Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. J Pediatr Hematol Oncol; 2006 Apr;28(4):210-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study.
  • This study was designed to evaluate the feasibility of enrolling children with recurrent ALL in a standardized treatment protocol that included receipt of a hematopoietic stem cell transplant (HSCT).
  • PROCEDURE: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin.
  • CONCLUSION: We conclude that well designed and controlled prospective studies are necessary to define the role of HSCTs in children with recurrent ALL.
  • [MeSH-major] Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation


19. Vieira L, Martinho A, Antunes O, Silva E, Ambrósio AP, Geraldes MC, Nascimento R, Silva C, Pereira JM, Júnior EC, Jordan P: Combined molecular diagnosis of B-cell lymphomas with t(11;14)(q13;q32) or t(14;18)(q32;q21) using multiplex- and long distance inverse-polymerase chain reaction. Diagn Mol Pathol; 2008 Jun;17(2):73-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular diagnosis of B-cell lymphomas with t(11;14)(q13;q32) or t(14;18)(q32;q21) using multiplex- and long distance inverse-polymerase chain reaction.
  • Translocations t(14;18)(q32;q21) and t(11;14)(q13;q32) are recurrent findings in follicular lymphoma (FL) and mantle cell lymphoma (MCL), respectively.
  • Taken together, we show that multiplex-PCR combined with long distance inverse-PCR detected a t(14;18) in 82% of FL patients and a t(11;14) in 91% of MCL patients, demonstrating that this 2-step protocol is an effective approach for molecular detection of t(11;14) and t(14;18) in B-cell lymphomas.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, B-Cell / diagnosis. Polymerase Chain Reaction / methods. Translocation, Genetic

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382373.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


20. Wong ET, Alsop D, Lee D, Tam A, Barron L, Bloom J, Gautam S, Wu JK: Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. Cerebrospinal Fluid Res; 2008 Jan 11;5:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas.
  • We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas.
  • METHODS: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251 glioma cell lines.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1828-35 [10206300.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] J Mol Med (Berl). 2000;78(5):261-8 [10954198.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Neuro Oncol. 2000 Jul;2(3):145-50 [11302334.001]
  • [Cites] J Neurochem. 1995 Mar;64(3):1312-8 [7532211.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 6;732:140-51 [7978787.001]
  • [Cites] Neurology. 1996 Jun;46(6):1626-32 [8649561.001]
  • [Cites] J Neurochem. 1996 Jul;67(1):251-9 [8666998.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):923-30 [9486583.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1951-2 [11419443.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1614-5 [11520815.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1383-8 [11870183.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4247-8 [12043695.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1777-82 [12685831.001]
  • [Cites] J Rheumatol. 1992 Jun;19(6):927-38 [1404131.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Dec;62(12):1254-64 [14692701.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):39-45 [14756439.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2044-6 [15470485.001]
  • [Cites] J Neurooncol. 2006 May;77(3):295-6 [16314946.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):305-8 [17324339.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • (PMID = 18186943.001).
  • [ISSN] 1743-8454
  • [Journal-full-title] Cerebrospinal fluid research
  • [ISO-abbreviation] Cerebrospinal Fluid Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115745
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2263020
  •  go-up   go-down


21. Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP: Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk; 2010 Jun;10(3):192-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
  • BACKGROUND: Patients with diffuse large B-cell lymphoma (DLBCL) who are not cured by initial therapy sometimes experience disease-free survival after autologous stem cell transplantation.
  • CONCLUSION: Our data demonstrate that patients with recurrent DLBCL not responding to second-line chemotherapy demonstrate dismal outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Stem Cell Transplantation. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20511164.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yeh S, Weichel ED, Faia LJ, Albini TA, Wroblewski KK, Stetler-Stevenson M, Ruiz P, Sen HN, Chan CC, Nussenblatt RB: 25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma. Br J Ophthalmol; 2010 May;94(5):633-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma.
  • BACKGROUND/AIMS Diagnostic pars plana vitrectomy is a useful technique in the diagnosis of intraocular lymphoma (IOL); however, the role of transconjunctival sutureless vitrectomy (TSV) has not been fully explored for this indication.
  • METHODS Patients who underwent 25-gauge TSV for the diagnosis of IOL (primary, secondary or recurrent) from two tertiary referral centres were reviewed.
  • B-cell or T-cell IOL was diagnosed based on cytology in 3/12 patients (25%, 95% CI 8.9 to 53.2%) and in eight patients (67%, 95% CI 39.1 to 86.1%) using adjunctive diagnostic testing.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Vitrectomy / methods

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2001 Apr;38(2):111-23 [11309693.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):464-72 [15080297.001]
  • [Cites] Am J Ophthalmol. 1991 Oct 15;112(4):472-4 [1928262.001]
  • [Cites] Ophthalmology. 1992 Feb;99(2):250-6 [1553217.001]
  • [Cites] Can J Ophthalmol. 1992 Jun;27(4):168-71 [1633587.001]
  • [Cites] Ophthalmology. 1993 May;100(5):705-14 [8493014.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1677-84 [8233394.001]
  • [Cites] Diagn Mol Pathol. 1992 Sep;1(3):173-9 [1342963.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):362-72 [9439362.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1664-9 [9754175.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2462-3 [10476821.001]
  • [Cites] Arch Ophthalmol. 1999 Sep;117(9):1239-42 [10496399.001]
  • [Cites] Ophthalmology. 2005 May;112(5):817-24 [15878061.001]
  • [Cites] Am J Ophthalmol. 2005 Nov;140(5):822-829 [16310459.001]
  • [Cites] Curr Opin Ophthalmol. 2007 May;18(3):188-93 [17435424.001]
  • [Cites] Br J Ophthalmol. 2007 Jul;91(7):945-8 [17202200.001]
  • [Cites] Ophthalmology. 2007 Oct;114(10):1893-7 [17509687.001]
  • [Cites] Retina. 2008 Feb;28(2):249-57 [18301030.001]
  • [Cites] Retina. 2008 Jul-Aug;28(7):941-6 [18698295.001]
  • (PMID = 20447965.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA EY000222-24
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS227989; NLM/ PMC2928256
  •  go-up   go-down


23. Almire C, Bertrand P, Ruminy P, Maingonnat C, Wlodarska I, Martín-Subero JI, Siebert R, Tilly H, Bastard C: PVRL2 is translocated to the TRA@ locus in t(14;19)(q11;q13)-positive peripheral T-cell lymphomas. Genes Chromosomes Cancer; 2007 Nov;46(11):1011-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PVRL2 is translocated to the TRA@ locus in t(14;19)(q11;q13)-positive peripheral T-cell lymphomas.
  • Very few recurrent chromosomal abnormalities have been identified in T-cell non-Hodgkin lymphomas.
  • We recently reported a novel and recurrent translocation, t(14;19)(q11;q13), in peripheral T-cell lymphoma (PTCL).
  • On chromosome 19, our results revealed a new clustering of breakpoints outside the region involved in t(14;19)(q32;q13)-positive B-cell malignancies.
  • In conclusion, we identified PVRL2 as a new recurrent partner gene of the TRA@ locus in PTCL.
  • [MeSH-major] Cell Adhesion Molecules / genetics. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 19. Lymphoma, T-Cell / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17696193.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / nectins
  •  go-up   go-down


24. Moradi S, Chavoshzadeh Z, Izadyar M, Mahjoub F, Rezaei N: Angiocentric nasal T-cell lymphoma in a patient withidiopathic CD4+ lymphocytopenia. Iran J Allergy Asthma Immunol; 2009 Dec;8(4):215-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiocentric nasal T-cell lymphoma in a patient withidiopathic CD4+ lymphocytopenia.
  • Idiopathic CD4+ Lymphocytopenia is a rare combined immunodeficiency disease, characterized by low CD4+ T-cell count and increased susceptibility to opportunistic infections, autoimmunity and malignancies after exclusion of secondary forms of CD4 lymphocytopenia.
  • He had a history of recurrent otitis media, chronic diarrhea, arthritis and herpetic lesions of eyes and mouth since the age of 5 years.
  • Immunohistological studies of destructive lesions in oral and nasal cavity revealed angiocentric T-cell lymphoma.
  • This patient is the first reported case of lethal midline granuloma with origin T-cell lymphoma in idiopathic CD4+ lymphocytopenia.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Lymphoma, T-Cell. Lymphopenia. Nose Neoplasms

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404393.001).
  • [ISSN] 1735-1502
  • [Journal-full-title] Iranian journal of allergy, asthma, and immunology
  • [ISO-abbreviation] Iran J Allergy Asthma Immunol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


25. Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC: Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer; 2007 Jan;46(1):37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a histopathologically well-defined entity.
  • However, despite a number of cytogenetic studies, the genetic basis of this lymphoma entity is not clear.
  • Moreover, there is an overlap to some cases of peripheral T-cell lymphoma unspecified (PTCL-u) in respect to morphological and genetic features.
  • The most recurrent changes in AILT were gains of 22q, 19, and 11p11-q14 (11q13) and losses of 13q.
  • Moreover, we could identify a recurrent gain of 11q13 in both AILT and PTCL-u, which has previously not been described in AILT.
  • In conclusion, CGH revealed common genetic events in peripheral T-cell lymphomas as well as peculiar differences between AILT and PTCL-u.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17044049.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kwon YJ, Lee JW, Kim MS, Jang PS, Chung NG, Jeong DC, Kim YG, Han KJ, Lee SJ, Cho B, Kim HK: Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea. Int J Hematol; 2009 Mar;89(2):150-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the patients with abnormal karyotypes, recurrent structural abnormalities were determined in 103 (78%) cases. t(12;21)(q13;q22) was found in 29 (22%) out of 132 patients, 9p abnormalities in 13 (10%) patients, t(1;19)(q23;p13.3) in 11 (8%) patients, t(9;22)(q34;q11.2) in 11 (8%) patients, and 11q23 abnormalities in 7 (5%) patients.
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


27. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R: High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma; 2009 Mar;9(1):39-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, few recurrent karyotypic abnormalities have been reported and the molecular consequences of these imbalances are largely unknown.
  • We used an array-based comparative genomic hybridization approach to better characterize the recurrent chromosome abnormalities associated with WM pathogenesis and to compare them with the publicly available findings in other B-cell neoplasias.
  • The majority of the recurrent chromosome abnormalities identified in WM were shared with marginal zone lymphomas (MZL), as deletions of 6q23 and 13q14 and gains of 3q13-q28, 6p and 18q.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 1;132(1):55-60 [11801310.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1271-7 [18931683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Blood. 1994 May 1;83(9):2611-8 [8167342.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1043-9 [8049424.001]
  • [Cites] Blood. 1996 Jan 1;87(1):299-307 [8547655.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jul 1;112(1):53-6 [10432937.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1634-6 [16838026.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Sep;169(2):150-3 [16938573.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2755-63 [16804116.001]
  • [Cites] Leukemia. 2007 Mar;21(3):541-9 [17252022.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3777-84 [17440091.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):700-20 [17672883.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):1-7 [17886247.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):477-87 [18297524.001]
  • [Cites] Haematologica. 2008 May;93(5):670-9 [18367492.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2996-3001 [12351413.001]
  • (PMID = 19362969.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083724; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / R01 CA136671; United States / NCI NIH HHS / CA / 01-CA62242; United States / NIA NIH HHS / AG / R01 AG020686; United States / NCI NIH HHS / CA / R01-CA83724-01; United States / NIA NIH HHS / AG / R01-AG020686; United States / NCI NIH HHS / CA / P50-CA100707-01; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / P50 CA100707; United States / NCI NIH HHS / CA / R01 CA133966; United States / NCI NIH HHS / CA / P50 CA097274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS455702; NLM/ PMC3646570
  •  go-up   go-down


28. Feys T, Poppe B, De Preter K, Van Roy N, Verhasselt B, De Paepe P, De Paepe A, Speleman F: A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines. Haematologica; 2007 Jul;92(7):913-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines.
  • BACKGROUND AND OBJECTIVES: Classical Hodgkin's lymphoma (cHL) is a common malignant lymphoma characterized by the presence of large, usually multinucleated malignant Hodgkin and Reed Sternberg (HRS) cells which are thought to be derived from germinal center B-cells.
  • DESIGN AND METHODS: In this study, we subjected four commonly used cHL cell lines to array comparative genomic hybridization (aCGH) in order to delineate known chromosomal aberrations in more detail and to search for small hitherto undetected genomic imbalances.
  • RESULTS: The aCGH profiles of the four cell lines tested confirmed the complex patterns of rearrangements previously demonstrated with M-FISH and chromosomal CGH (cCGH).
  • Furthermore, we detected 35 hitherto undetected aberrations including a homozygous deletion of chromosomal region 15q26.2 in the cell line HDLM2 encompasing RGMA and CHD2 and an amplification of the STAT6 gene in cell line L1236 leading to STAT6 overexpression.
  • Finally, in cell line KM-H2 we found a 2.35 Mb deletion at 16q12.1 putatively defining a small critical region for the recurrent 16q deletion in cHL.
  • INTERPRETATION AND CONCLUSIONS: aCGH was performed on four cHL cell lines leading to the improved delineation of known chromosomal imbalances and the detection of 35 hitherto undetected aberrations.
  • [MeSH-major] Gene Dosage. Hodgkin Disease / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosome Aberrations. Cytogenetic Analysis. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / genetics. STAT6 Transcription Factor / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606441.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


29. Hartmann S, Martin-Subero JI, Gesk S, Hüsken J, Giefing M, Nagel I, Riemke J, Chott A, Klapper W, Parrens M, Merlio JP, Küppers R, Bräuninger A, Siebert R, Hansmann ML: Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica; 2008 Sep;93(9):1318-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
  • BACKGROUND: Cytogenetic analysis of classical Hodgkin's lymphoma is limited by the low content of the neoplastic Hodgkin-Reed-Sternberg cells in the affected tissues.
  • To obtain insights into chromosomal imbalances in classical Hodgkin's lymphoma, we applied array-based comparative genomic hybridization (array comparative genomic hybridization) using DNA from microdissected Hodgkin-Reed-Sternberg cells.
  • DESIGN AND METHODS: To avoid biases introduced by DNA amplification for array comparative genomic hybridization, cHL cases rich in Hodgkin-Reed-Sternberg cells were selected.
  • DNA obtained from approximately 100,000 microdissected Hodgkin-Reed-Sternberg cells of each of ten classical Hodgkin's lymphoma cases was hybridized onto commercial 105 K oligonucleotide comparative genomic hybridization microarrays.
  • Selected imbalances were confirmed by interphase cytogenetics and quantitative polymerase chain reaction analysis and further studied in an independent series of classical Hodgkin's lymphoma.
  • RESULTS: Gains identified in at least five cHL affected 2p12-16, 5q15-23, 6p22, 8q13, 8q24, 9p21-24, 9q34, 12q13-14, 17q12, 19p13, 19q13 and 20q11 whereas losses recurrent in at least five cases involved Xp21, 6q23-24 and 13q22.
  • Among these, gains of STAT6 (12q13), NOTCH1 (9q34) and JUNB (19p13) were present in additional cHL with the usual low Hodgkin-Reed-Sternberg cell content.
  • CONCLUSIONS: The present study demonstrates that array comparative genomic hybridization of microdissected Hodgkin-Reed-Sternberg cells is suitable for identifying and characterizing chromosomal imbalances.
  • Regions affected by genomic changes in Hodgkin-Reed-Sternberg cells recurrently include genes constitutively expressed in cHL.
  • [MeSH-major] Genome, Human / genetics. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Sep;93(9):1292-5 [18757849.001]
  • (PMID = 18641027.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


30. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther; 2006 Aug;5(8):928-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent KRAS codon 146 mutations in human colorectal cancer.
  • We report here the identification of recurrent somatic missense mutations at alanine 146, a highly conserved residue in the guanine nucleotide binding domain.
  • We also detected KRAS A146 mutations in 2/40 (5%) colorectal cell lines, including the NCI-60 colorectal cancer line HCC2998.
  • Lung adenocarcinomas and large cell carcinomas did not show codon 146 mutations.
  • We did, however, identify a KRAS A146 mutation in the ML-2 acute myeloid leukemia cell line and an NRAS A146 mutation in the NALM-6 B-cell acute lymphoblastic leukemia line, suggesting that the contribution of codon 146 mutations is not entirely restricted to colorectal cancers or to KRAS.
  • [MeSH-minor] Adenocarcinoma / genetics. Amino Acid Sequence. Carcinoma, Large Cell / genetics. DNA Mutational Analysis. DNA, Neoplasm / genetics. Hong Kong. Humans. Leukemia, Myeloid, Acute / genetics. Molecular Sequence Data. Neoplasm Staging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Homology, Amino Acid. United States

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1334-8 [418410.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):143-9 [6290897.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):149-52 [7133135.001]
  • [Cites] Mol Cell Biol. 1988 Jun;8(6):2472-8 [3043178.001]
  • [Cites] Carcinogenesis. 1988 Nov;9(11):2073-9 [2902939.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):405-8 [2403644.001]
  • [Cites] Virus Genes. 1991 Jan;5(1):75-9 [2017878.001]
  • [Cites] Hum Mutat. 1996;8(3):258-61 [8889585.001]
  • [Cites] Mutat Res. 2004 Nov;567(2-3):447-74 [15572290.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1299-304 [11701921.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • (PMID = 16969076.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / CA062924; United Kingdom / Wellcome Trust / / 077012
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2714972; NLM/ UKMS27311
  •  go-up   go-down


31. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A: Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia; 2009 Mar;23(3):574-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
  • Oncogenes involved in recurrent chromosomal translocations serve as diagnostic markers and therapeutic targets in hematopoietic tumors.
  • In contrast to myeloid and B-cell neoplasms, translocations in peripheral T-cell lymphomas (PTCLs) are poorly understood.
  • Here, we identified recurrent translocations involving the multiple myeloma oncogene-1/interferon regulatory factor-4 (IRF4) locus in PTCLs.
  • IRF4 translocations exist in myeloma and some B-cell lymphomas, but have not been reported earlier in PTCLs.
  • Two cases with t(6;14)(p25;q11.2) had translocations between IRF4 and the T-cell receptor-alpha (TCRA) locus.
  • In total, 8 of the remaining 10 cases were cutaneous anaplastic large-cell lymphomas (ALCLs) without TCRA rearrangements (57% of cutaneous ALCLs tested).
  • These findings identified IRF4 translocations as a novel recurrent genetic abnormality in PTCLs.
  • Detecting these translocations may be useful in lymphoma diagnosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):1-9 [11520558.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leukemia. 2006 Feb;20(2):313-8 [16341044.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] J Pathol. 2007 Sep;213(1):99-105 [17582237.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Nov;46(11):1011-8 [17696193.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):557-63 [18234282.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3867-71 [18235046.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Br J Dermatol. 2008 Jun;158(6):1280-7 [18410414.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):178-85 [18628085.001]
  • [Cites] Histopathology. 2000 Feb;36(2):136-44 [10672058.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):773-9 [12428799.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):176-85 [12696066.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Leuk Res. 1985;9(9):1139-48 [3877852.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] J Invest Dermatol. 1997 Nov;109(5):636-40 [9347791.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):114-21 [9598798.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):228-36 [10029454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):319-29 [10478136.001]
  • [Cites] Leukemia. 2005 Jan;19(1):77-82 [15510210.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2247-53 [16193085.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:131-5 [10707795.001]
  • (PMID = 18987657.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P50 CA097274-07; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS70248; NLM/ PMC2656414
  •  go-up   go-down


32. Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1092-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
  • The aim of this study was to determine the feasibility, efficacy and toxicity of the combined therapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL).
  • Thirty six patients, 14 with mantle cell lymphoma (MCL), 10 with diffuse large B-cell lymphoma (DLBCL), 5 with follicular lymphoma (FL), 3 with small lymphocytic lymphoma (SLL), and 4 with T-cell lymphoma were enrolled to the study.
  • When different disease status before CMC treatment was considered, a trend toward longer survival of recurrent patients was observed (log rank test, P = 0.08).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology

  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; CMC protocol 2
  •  go-up   go-down


33. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, Morishima Y, Nakamura S, Seto M: Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene; 2005 Feb 17;24(8):1348-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.
  • Mantle cell lymphoma (MCL) is characterized by 11q13 chromosomal translocation and CCND1 overexpression, but additional genomic changes are also important for lymphomagenesis.
  • To identify the genomic aberrations of MCL at higher resolutions, we analysed 29 patient samples and seven cell lines using array-based comparative genomic hybridization (array CGH) consisting of 2348 artificial chromosome clones, which cover the whole genome at a 1.3 mega base resolution.
  • Our analyses also detected several novel recurrent regions of loss located at 1p36, 1q42.2-q43, 2p11.2, 2q13, 17p13.3 and 19p13.2-p13.3, as well as recurrent regions of homozygous loss such as 2p11 (Ig(kappa)), 2q13 and 9p21.3-p24.1 (INK4a/ARF).
  • [MeSH-major] Apoptosis / genetics. Carrier Proteins / genetics. Chromosomal Instability / genetics. Gene Deletion. Lymphoma, Mantle-Cell / genetics. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis Regulatory Proteins. Cell Line, Tumor. Chromosomes, Human / genetics. Female. Genome, Human. Homozygote. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608680.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Carrier Proteins; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


34. Hagen L, Peña-Diaz J, Kavli B, Otterlei M, Slupphaug G, Krokan HE: Genomic uracil and human disease. Exp Cell Res; 2006 Aug 15;312(14):2666-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients lacking UNG2 display a hyper-IgM syndrome with recurrent infections, increased IgM, strongly decreased IgG, IgA and IgE and skewed SHM.
  • Ung(-/-) mice have a similar phenotype and develop B-cell lymphomas late in life.
  • [MeSH-minor] Animals. Humans. Immunity. Lymphoma, B-Cell / genetics. Mice. Models, Genetic. Somatic Hypermutation, Immunoglobulin. Uracil-DNA Glycosidase / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860315.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 56HH86ZVCT / Uracil; 9007-49-2 / DNA; EC 3.2.2.- / CCNO protein, human; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / Uracil-DNA Glycosidase
  • [Number-of-references] 35
  •  go-up   go-down


35. Mrózek K: Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol; 2008 Aug;35(4):365-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The emerging nonrandom pattern of abnormalities includes relative paucity, but not absence, of balanced rearrangements (translocations, insertions, or inversions), predominance of aberrations leading to loss of chromosome material (monosomies, deletions, and unbalanced translocations) that involve, in decreasing order, chromosome arms 5q, 17p, 7q, 18q, 16q, 17q, 12p, 20q, 18p, and 3p, and the presence of recurrent, albeit less frequent and often hidden (in marker chromosomes and unbalanced translocations) aberrations leading to overrepresentation of segments from 8q, 11q, 21q, 22q, 1p, 9p, and 13q.
  • They can be improved to some extent by allogeneic stem cell transplantation in younger patients.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1151-2; author reply 1152-3 [17369586.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1037-48 [17347684.001]
  • [Cites] Eur J Haematol. 2007 Jun;78(6):468-76 [17419750.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Jun;175(2):125-31 [17556068.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4603-9 [18559876.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2113-9 [15951308.001]
  • [Cites] Hematol Oncol. 2005 Mar;23(1):18-25 [16142824.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] Nat Med. 2006 Jan;12(1):114-21 [16369543.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Jan;4(1):37-50 [16403403.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] Hum Mol Genet. 2006 Mar 15;15(6):933-42 [16452126.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 15;168(2):133-45 [16843103.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Sep;45(9):798-807 [16736498.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3887-94 [16864856.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3280-8 [16840728.001]
  • [Cites] Leuk Res. 2007 Jan;31(1):39-47 [16687173.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Nat Med. 2007 Jan;13(1):78-83 [17159988.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):16-25 [15325089.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1072-81 [15377468.001]
  • [Cites] Lancet. 1985 Nov 9;2(8463):1035-9 [2865517.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):358-71 [15645489.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):227-38 [15846790.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Sep;161(2):125-9 [16102582.001]
  • [Cites] Blood. 1991 Oct 1;78(7):1652-7 [1912553.001]
  • [Cites] Leukemia. 1995 Mar;9(3):370-81 [7885035.001]
  • [Cites] Leuk Res. 1995 Dec;19(12):905-13 [8632659.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):17-31 [9045301.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3158-68 [9738588.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1025-31 [9920852.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Sep;26(1):13-9 [10441000.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):166-70 [10469455.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):380-6 [10719368.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1031-8 [10865969.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):40-7 [10918392.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1885-91 [11069023.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jan;30(1):15-24 [11107171.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Int J Hematol. 2000 Oct;72(3):261-71 [11185980.001]
  • [Cites] Br J Haematol. 2000 Dec;111(3):801-6 [11122141.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):118-26 [11167792.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 1;124(1):1-6 [11165314.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 1;124(1):7-11 [11165315.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1405-13 [11230485.001]
  • [Cites] Br J Haematol. 2001 May;113(2):305-17 [11380393.001]
  • [Cites] Leukemia. 2001 Jun;15(6):903-9 [11417475.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1133-6 [11455985.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Haematologica. 2001 Nov;86(11):1158-64 [11694401.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jan;33(1):60-72 [11746988.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):42-7 [11921281.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jun;34(2):137-53 [11979548.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):20-9 [12203786.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):406-12 [12619165.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Nov;38(3):249-52 [14506699.001]
  • [Cites] Leukemia. 2004 Jan;18(1):120-5 [14586477.001]
  • [Cites] Blood. 2004 Jan 1;103(1):229-35 [12946992.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1843-53 [14738135.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3915-20 [15007164.001]
  • [Cites] Haematologica. 2004 Apr;89(4):408-18 [15075074.001]
  • [Cites] Br J Haematol. 2004 Aug;126(3):320-37 [15257704.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5675-87 [16110027.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):96-105 [17129222.001]
  • (PMID = 18692687.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 77658; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA 16058; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / CA 101140; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  • [Other-IDs] NLM/ NIHMS66054; NLM/ PMC3640813
  •  go-up   go-down


36. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A: T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia; 2005 Apr;19(4):652-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.
  • The three chromosomal translocations t(11;18)(q21;q21), t(14;18)(q32;q21), and t(1;14)(p22;q32) are associated with MALT lymphoma.
  • In a case of MALT lymphoma of the thyroid, we observed t(3;14)(p14.1;q32) by cytogenetic analysis.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 3. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell, Marginal Zone / genetics. Repressor Proteins / genetics. Translocation, Genetic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2006 Jul;20(7):1300-3 [16673020.001]
  • (PMID = 15703784.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / FOXP1 protein, human; 0 / Forkhead Transcription Factors; 0 / Immunoglobulin Heavy Chains; 0 / Neoplasm Proteins; 0 / Repressor Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


37. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ: Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res; 2007 Oct 15;13(20):6168-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Patients with relapsed/refractory CD20+ B cell non-Hodgkin's lymphoma received i.v. rituximab (375 mg/m2/week for 4 weeks) and PF-3512676 weekly for 4 weeks either i.v. (0.04, 0.16, 0.32, or 0.48 mg/kg) or s.c. (0.01, 0.04, 0.08, or 0.16 mg/kg).
  • CONCLUSION: Brief or extended-duration PF-3512676 can be safely administered in combination with rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Oligodeoxyribonucleotides / administration & dosage. Toll-Like Receptors / agonists

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


38. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol; 2006 Aug 20;24(24):3880-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
  • PURPOSE: A multicenter, single-arm study examining efficacy and toxicity of epratuzumab combined with rituximab was conducted in patients with recurrent or refractory non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Sixty-five patients were enrolled; 34 patients with follicular lymphoma (FL), 15 patients with diffuse large B-cell lymphoma (DLBCL), and 16 patients with other lymphomas.
  • Two of six patients with marginal zone lymphoma responded to treatment (one CR).
  • There was a trend for the response rates to be higher in patients with low prognostic index scores (statistically significant with respect to the Follicular Lymphoma International Prognostic Index score in FL patients), with 12 FL patients and three DLBCL patients in groups 0 to 1 having OR (CR/CRu) rates of 83% (33%) and 100% (100%), respectively.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, B-Cell / drug therapy. Sialic Acid Binding Ig-like Lectin 2 / immunology

  • Hazardous Substances Data Bank. RITUXIMAB .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


39. Yiannias JA, DiCaudo DJ, Maskin E: Peripheral T-cell lymphoma presenting as lipoatrophy and nodules. Int J Dermatol; 2006 Dec;45(12):1415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma presenting as lipoatrophy and nodules.
  • Lymphoma presents rarely with a constellation of nodules, panniculitis, and localized lipoatrophy.
  • The histopathologic similarities of lymphoma and connective tissue disease panniculitis may create a diagnostic challenge.
  • METHODS: We retrospectively reviewed the case of a 47-year-old man who presented 15 years earlier with recurrent fevers, fatigue, tender subcutaneous nodules, and facial, trunk, and extremity lipoatrophy.
  • Biopsy of a new chin nodule indicated peripheral T-cell lymphoma, whereas an evaluation for systemic malignant involvement was negative.
  • CONCLUSIONS: We report a rare case of lymphoma presenting as nodules and profound lipoatrophy, which exemplifies the complexity of lymphomas.
  • Profound lipoatrophy and panniculitis may be an unusual and diagnostically challenging presentation of cutaneous lymphoma.
  • [MeSH-major] Lipodystrophy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Panniculitis, Lupus Erythematosus / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184242.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Kearney L, Horsley SW: Molecular cytogenetics in haematological malignancy: current technology and future prospects. Chromosoma; 2005 Sep;114(4):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytogenetics has played a pivotal role in haematological malignancy, both as an aid to diagnosis and in identifying recurrent chromosomal rearrangements, an essential prerequisite to identifying genes involved in leukaemia and lymphoma pathogenesis.
  • [MeSH-minor] Child. Humans. In Situ Hybridization, Fluorescence. Nucleic Acid Hybridization. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):383-92 [11241791.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2202-6 [12931229.001]
  • [Cites] Leukemia. 2004 May;18(5):895-908 [15042105.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1031-8 [10865969.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1425-9 [12618769.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1827-37 [15229187.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3010-5 [12829594.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):18-24 [10094809.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Blood. 2004 Aug 1;104(3):795-801 [15090459.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):149-58 [12696063.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):3-10 [11328273.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1153-6 [15057249.001]
  • [Cites] Genome Res. 2004 Mar;14(3):414-25 [14993208.001]
  • [Cites] Blood. 2002 Aug 1;100(3):991-7 [12130513.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2249-50 [14523475.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):318-28 [10862038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3109-17 [12406872.001]
  • [Cites] Science. 1996 Jul 26;273(5274):494-7 [8662537.001]
  • [Cites] Blood. 1992 Jul 1;80(1):203-8 [1351763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1039-44 [14730057.001]
  • [Cites] Blood. 2002 Jul 1;100(1):347-9 [12070048.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):368-75 [8630489.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Leukemia. 2005 Mar;19(3):358-66 [15674412.001]
  • [Cites] Chromosome Res. 2004;12(1):15-23 [14984098.001]
  • [Cites] Br J Cancer. 2001 Feb;84(4):499-503 [11207045.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):38-43 [15034866.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2756-62 [12829593.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):191-202 [15334542.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):250-9 [15254283.001]
  • [Cites] Haematologica. 2004 Jun;89(6):671-8 [15194534.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):20-9 [12203786.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]
  • [Cites] Genome Res. 2004 Feb;14(2):287-95 [14762065.001]
  • [Cites] Eur J Hum Genet. 1999 Jan;7(1):2-11 [10094185.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9197-202 [11481483.001]
  • [Cites] Leukemia. 2003 Mar;17(3):547-53 [12646943.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R145-52 [12915456.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2222-7 [12399965.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 09;32(12):3651-60 [15247347.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jan;33(1):60-72 [11746988.001]
  • [Cites] Leukemia. 2002 Jan;16(1):7-12 [11840257.001]
  • [Cites] Leukemia. 2001 Jan;15(1):177-83 [11243387.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):247-55 [15621809.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jun;34(2):137-53 [11979548.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Leukemia. 2001 Mar;15(3):468-72 [11237073.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):348-57 [11071357.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Sep;14(3):593-607 [11640871.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):361-74 [12619160.001]
  • [Cites] Genome Res. 2004 Jan;14(1):179-87 [14672980.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2526-31 [11895789.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 16003502.001).
  • [ISSN] 0009-5915
  • [Journal-full-title] Chromosoma
  • [ISO-abbreviation] Chromosoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Austria
  • [Number-of-references] 66
  •  go-up   go-down


41. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia; 2007 Jun;21(6):1183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
  • Here, we report on seven FIP1L1-PDGFRA-positive patients who presented with acute myeloid leukemia (AML, n=5) or lymphoblastic T-cell non-Hodgkin-lymphoma (n=2) in conjunction with AML or Eos-MPD.
  • [MeSH-major] Eosinophilia / drug therapy. Leukemia, Myeloid / drug therapy. Oncogene Proteins, Fusion / analysis. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Receptor, Platelet-Derived Growth Factor alpha. mRNA Cleavage and Polyadenylation Factors


42. Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ: Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant; 2005 Feb;11(2):129-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
  • Autologous hematopoietic stem cell transplantation (AHSCT) in low-grade non-Hodgkin lymphoma (NHL) can result in a prolonged remission, although most patients eventually relapse and die of their disease.
  • Recurrent lymphoma after AHSCT remains the major problem, and prolonged survival is further tempered by a significant risk of post-transplantation second malignancies, including myelodysplastic syndrome/acute myeloid leukemia and solid tumors.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / mortality

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682074.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ohtsuka R, Abe Y, Sada E, Kiyasu J, Ashikari A, Shiratsuchi M, Nishimura J, Takayanagi R, Ohshima K: Adult patient with Epstein-Barr virus (EBV)-associated lymphoproliferative disorder: chronic active EBV infection or de novo extranodal natural killer (NK)/T-cell lymphoma, nasal type? Intern Med; 2009;48(6):471-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult patient with Epstein-Barr virus (EBV)-associated lymphoproliferative disorder: chronic active EBV infection or de novo extranodal natural killer (NK)/T-cell lymphoma, nasal type?
  • Chronic active Epstein-Barr virus (EBV) infection, which is considered to be a childhood disease, often develops into natural killer (NK) or T-cell lymphoma after recurrent infectious mononucleosis (IM)-like symptoms.
  • We describe a 56-year-old woman who developed NK-cell lymphoma after 9 months of recurrent IM-like symptoms.
  • Several chemotherapy regimens were ineffective, and the patient died of progression of lymphoma.
  • Certain subtypes of NK-cell lymphoma showing a long-lasting prodrome related to chronic EBV infection may exist.
  • [MeSH-major] Antibodies, Viral / analysis. Epstein-Barr Virus Infections / diagnosis. Herpesvirus 4, Human / immunology. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoproliferative Disorders / diagnosis. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Epstein Barr Virus, Chronic.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293549.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


44. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA: Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol; 2005 Oct;29(10):1348-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory myofibroblastic tumor (IMT) is an indolent spindle cell proliferation that can histologically resemble various malignant mesenchymal neoplasms; however, it generally behaves as a benign or locally recurrent tumor.
  • We report the clinical and pathologic features of six IMTs of the uterus, one of which was included in a previous report, and emphasize the histologic and immunohistochemical features that distinguish IMTs from uterine spindle cell neoplasms that require aggressive treatment.
  • Recently, translocations of the anaplastic lymphoma kinase (ALK) gene and immunohistochemical expression of ALK have been reported in IMTs of various anatomic sites.

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


45. Zhou Y, Barlogie B, Shaughnessy JD Jr: The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia; 2009 Nov;23(11):1941-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer-causing mutations disrupt coordinated, precise programs of gene expression that govern cell growth and differentiation.
  • Unique expression patterns associated with recurrent chromosomal translocations and ploidy changes defined molecular classes with differing clinical features and outcomes.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Oct 20;24(46):6936-44 [16044163.001]
  • [Cites] Blood. 2006 Jan 1;107(1):222-31 [16144803.001]
  • [Cites] Br J Haematol. 2006 Apr;133(1):83-92 [16512833.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Blood. 2006 May 1;107(9):3669-75 [16373658.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2175-86 [12200383.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1128-40 [12393520.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1520-9 [12393535.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2374-6 [12433679.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Blood. 2003 May 1;101(9):3606-14 [12480690.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Blood. 2003 May 15;101(10):3849-56 [12531801.001]
  • [Cites] Cancer Treat Rev. 2003 May;29 Suppl 1:11-9 [12738239.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3025-34 [9787135.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1293-301 [9809554.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17765-70 [15591353.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2461-73 [15735737.001]
  • [Cites] Blood. 2005 May 15;105(10):3939-44 [15671442.001]
  • [Cites] Transplantation. 2005 May 15;79(9):1180-3 [15880066.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4251-8 [15930364.001]
  • [Cites] Blood. 2005 Jul 1;106(1):296-303 [15755896.001]
  • [Cites] Blood. 1996 Jul 15;88(2):674-81 [8695815.001]
  • [Cites] Genome Res. 1996 Jul;6(7):639-45 [8796352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10614-9 [8855227.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jun;19(2):124-33 [9172003.001]
  • [Cites] Blood. 1998 Apr 15;91(8):3007-10 [9531613.001]
  • [Cites] Science. 1998 Jul 24;281(5376):533-8 [9677190.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1288-90 [16688228.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4257-66 [16518413.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(11):1581-90 [16797965.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):3307-15 [17312182.001]
  • [Cites] Leukemia. 2007 Mar;21(3):582-4 [17215851.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2276-84 [17105813.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Bone Marrow Transplant. 2004 Aug;34(3):235-9 [15170170.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5692-701 [15355895.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1217-22 [15195108.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2661-6 [15238415.001]
  • [Cites] Recent Results Cancer Res. 1978;65:12-20 [370937.001]
  • [Cites] Hematol Oncol. 1988 Apr-Jun;6(2):107-13 [3391529.001]
  • [Cites] Science. 1991 Feb 15;251(4995):767-73 [1990438.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1253-60 [7992829.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4250-6 [7492784.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1724-32 [16705089.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] Br J Haematol. 2006 Oct;135(1):52-61 [16925573.001]
  • [Cites] Oncogene. 2006 Nov 16;25(54):7180-91 [16732320.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4194-7 [16946299.001]
  • [Cites] Haematologica. 2007 Jan;92(1):56-65 [17229636.001]
  • [Cites] Methods Mol Med. 2005;113:25-35 [15968092.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1021-30 [15827134.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5334-46 [15939924.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):729-32 [16115129.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6333-8 [16155016.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7296-306 [16129847.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):565-73 [17367409.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3177-88 [17185464.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2982-9 [17409404.001]
  • [Cites] Leukemia. 2007 May;21(5):1113-6 [17315022.001]
  • [Cites] Leukemia. 2007 May;21(5):1079-88 [17344918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7516-21 [17452641.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4914-23 [17339423.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):115-30 [17692804.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1109-18 [17823926.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3291-300 [17609426.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2519-26 [17882285.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):44-54 [18172295.001]
  • [Cites] Blood. 2008 Jan 15;111(2):968-9 [18182586.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1603-9 [18006703.001]
  • [Cites] Leukemia. 2008 Feb;22(2):459-61 [17805328.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4821-9 [18676754.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1329-37 [17906076.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4798-805 [18591550.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):520-31 [18986388.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4235-46 [18337559.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4017-23 [18669875.001]
  • [Cites] Exp Hematol. 2009 Jan;37(1):78-86 [19013005.001]
  • [Cites] Haematologica. 2009 Jan;94(1):78-86 [19059936.001]
  • [Cites] Blood. 2009 Jan 15;113(3):517-25 [18687985.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1343-52 [19190130.001]
  • [Cites] Br J Haematol. 2009 Apr;145(1):45-58 [19183193.001]
  • [Cites] Exp Hematol. 2009 Apr;37(4):446-9 [19211183.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3781-91 [19020308.001]
  • [Cites] Br J Haematol. 2009 May;145(3):350-68 [19298595.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4309-18 [19196658.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3058-67 [19383820.001]
  • [Cites] Blood. 2003 Jul 15;102(2):592-600 [12663452.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):728-44 [12930383.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9 [12941866.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8749-56 [14695190.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5 [14695887.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1799-806 [12969976.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8047-55 [14630925.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):221-30 [15050914.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Mol Endocrinol. 2007 Feb;21(2):486-98 [17068196.001]
  • [Cites] Blood. 2009 May 7;113(19):4614-26 [19228610.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):603-14 [19396863.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6572-5 [19389881.001]
  • [Cites] Blood. 2009 Jul 2;114(1):128-43 [19299335.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2068-76 [19443657.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1369-78 [16923571.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1304-51 [11181995.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2001 Jul 1;98(1):217-23 [11418483.001]
  • [Cites] Blood. 2001 Aug 1;98(3):771-80 [11468178.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1346-58 [11857078.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1745-57 [11861292.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1113-22 [12149187.001]
  • (PMID = 19657360.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055819; United States / NCI NIH HHS / CA / R33 CA097513; United States / NCI NIH HHS / CA / CA55819-09; United States / NCI NIH HHS / CA / CA97513-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 138
  • [Other-IDs] NLM/ NIHMS454462; NLM/ PMC3686133
  •  go-up   go-down


46. Michaux L, Wlodarska I, Rack K, Stul M, Criel A, Maerevoet M, Marichal S, Demuynck H, Mineur P, Kargar Samani K, Van Hoof A, Ferrant A, Marynen P, Hagemeijer A: Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL. Leukemia; 2005 Jan;19(1):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL.
  • Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder.
  • Three cases developed transformation into diffuse large B-cell lymphoma.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 6. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Translocation, Genetic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510210.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Graham BB, Mathisen DJ, Mark EJ, Takvorian RW: Primary pulmonary lymphoma. Ann Thorac Surg; 2005 Oct;80(4):1248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary lymphoma.
  • BACKGROUND: Primary pulmonary lymphoma is a rare disease.
  • METHODS: A retrospective review of primary pulmonary lymphoma cases at a single institution from 1990 to 2002 was performed.
  • Fourteen patients had mucosa-associated lymphoid tissue (MALT) lymphoma, 2 had large cell transformation of sheet cells in MALT lymphoma, and 1 each had Hodgkin's disease and follicular lymphoma.
  • Patients who had bilateral disease were more likely to have recurrent disease or death (p = 0.03).
  • CONCLUSIONS: A wide range of treatments were used for patients with generally MALT lymphoma, resulting in good outcomes, and recurrent disease was well controlled.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Hodgkin Disease / pathology. Hodgkin Disease / radiography. Hodgkin Disease / surgery. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiography. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radiography. Lymphoma, Follicular / surgery. Male. Middle Aged. Neoplasm Staging / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181848.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


48. Song EK, Kim SY, Kim TM, Lee KW, Yun T, Na II, Shin H, Lee SH, Kim DW, Khwarg SI, Heo DS: Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol; 2008 Feb;19(2):242-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma.
  • BACKGROUND: Radiotherapy is commonly used as a first-line treatment for localized ocular adnexal extranodal marginal zone B-cell lymphoma (EMZBL), despite its ophthalmologic complications.
  • Chemotherapy was followed by radiotherapy only in recurrent cases.
  • CONCLUSIONS: Front-line CVP, in conjunction with radiotherapy in recurrent cases, is effective and well tolerated in patients with localized ocular adnexal EMZBL.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947227.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


49. Baysal BE: A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One; 2007 May 09;2(5):e436
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.
  • Here, I describe that succinate dehydrogenase (SDH; mitochondrial complex II) subunit B gene (SDHB) is somatically mutated at a cytidine residue in normal peripheral blood mononuclear cells (PBMCs) and T-cell acute leukemia.
  • Examination of the PBMC cell-type subsets identifies monocytes and natural killer (NK) cells as primary sources of the mutant transcript, although lesser contributions also come from B and T lymphocytes.
  • Transcript sequence analyses in leukemic cell lines derived from monocyte, NK, T and B cells indicate that the mutational mechanism targeting SDHB is operational in T-cell acute leukemia.
  • Accordingly, substantial levels (more than 3%) of the mutant SDHB transcripts are detected in five of 20 primary childhood T-cell acute lymphoblastic leukemia (T-ALL) bone marrow samples, but in none of 20 B-ALL samples.
  • In addition, distinct heterozygous SDHB missense DNA mutations are identified in Jurkat and TALL-104 cell lines which are derived from T-ALLs.
  • CONCLUSIONS: The identification of a recurrent, inactivating stop-codon mutation in the SDHB gene in normal blood cells suggests that SDHB is targeted by a cytidine deaminase enzyme.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):180-91 [10485273.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Anal Biochem. 2007 Jan 1;360(1):84-91 [17107651.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):7-10 [17190841.001]
  • [Cites] BMC Biol. 2007;5:12 [17376234.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):715-21 [15649883.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):375-6 [10932175.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):38-50 [11727199.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] Trends Genet. 2003 Apr;19(4):207-16 [12683974.001]
  • [Cites] Annu Rev Genet. 1990;24:305-26 [2088171.001]
  • (PMID = 17487275.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA11236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC1855983
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


50. Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E: Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol; 2009 Feb;144(3):367-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those with successful eradication of H. pylori and no evidence of progression of lymphoma were eligible for randomisation to chlorambucil or observation.
  • With a median follow-up of 58 months, six patients were dead and 17 had recurrent/progressive disease.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chlorambucil / therapeutic use. Helicobacter Infections / prevention & control. Lymphoma, B-Cell, Marginal Zone / microbiology. Neoplasm Recurrence, Local / prevention & control. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2541-4 [11895791.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1286-94 [11984515.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):28-37 [15213615.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Histopathology. 1987 May;11(5):445-62 [3497084.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2524-9 [7595703.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):527-37 [9389360.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5061-6 [16051953.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6415-20 [16155028.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] Gut. 2007 Dec;56(12):1685-7 [17639089.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):521-38 [17156403.001]
  • [CommentIn] Curr Hematol Malig Rep. 2009 Jul;4(3):113-4 [20425423.001]
  • (PMID = 19036078.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil
  • [Other-IDs] NLM/ PMC2659366
  •  go-up   go-down


51. De Waele M, Hendriks J, Lauwers P, Van Schil P: Different indications for repeat mediastinoscopy: single institution experience of 79 cases. Minerva Chir; 2009 Aug;64(4):415-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presently, it is a valuable restaging tool in non-small cell lung cancer (NSCLC).
  • RESULTS: ReMS was performed after induction therapy in 54 cases (68.4%), for recurrent lung cancer in 7 cases (8.9%), metachronous second primary lung cancer in 2 cases (2.5%), for lung cancer occurring after an unrelated disease such as sarcoidosis in 1 case (1.2%), for an inadequate first procedure in 8 cases (10.1%) and for a non-malignant disease such as sarcoidosis or lymphoma in 7 cases (8.9%).
  • ReMS provided a definitive diagnosis in 3 patients with sarcoidosis and in one patient with lymphoma .
  • CONCLUSIONS: Although mostly performed as a restaging procedure after induction therapy in non-small cell lung cancer, reMS can also safely be performed for other indications providing pathological evidence of mediastinal involvement.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Mediastinoscopy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648861.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Stevens SJ, Meers LE, Albrechts JC, Mebis-Verhees K, Bos GM, Engelen JJ, Janssen JW: A translocation in acute lymphoblastic leukemia that cytogenetically mimics the recurrent MLL-AFF1 translocation and fuses SEPT11 to MLL. Cancer Genet Cytogenet; 2010 Aug;201(1):48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A translocation in acute lymphoblastic leukemia that cytogenetically mimics the recurrent MLL-AFF1 translocation and fuses SEPT11 to MLL.
  • This MLL-SEPT11 fusion is cytogenetically indistinguishable from the recurrent t(4;11)(q21;q23).
  • Thus, it is crucial to characterize cytogenetic aberrations in leukemia by molecular methods, even in cases where a known recurrent translocation is presumed.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Gene Fusion. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633769.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.1.- / SEPT11 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


53. Anderson VR, Perry CM: Fludarabine: a review of its use in non-Hodgkin's lymphoma. Drugs; 2007;67(11):1633-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine: a review of its use in non-Hodgkin's lymphoma.
  • Fludarabine (Fludara), a purine nucleoside analogue, has been extensively evaluated in the treatment of a number of lymphoproliferative malignancies, including various types of non-Hodgkin's lymphoma.
  • Clinical studies have shown that fludarabine (alone, and particularly as a component of combination therapy) can result in high overall and complete response in adults with various types of non-Hodgkin's lymphoma, including follicular lymphoma.
  • As mono- or combination therapy, intravenous fludarabine is as effective as several other standard treatment regimens in treatment-naive patients and is also effective in patients with recurrent or refractory disease.
  • The once-daily oral formulation was effective in the treatment of patients with relapsed indolent B-cell non-Hodgkin's lymphoma; however, further studies are required to confirm its role and establish its efficacy relative to that of standard treatment in this patient population.
  • Fludarabine, therefore, provides a highly effective first- or second-line option in the treatment of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):546-53 [10080598.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2640-4 [11675332.001]
  • [Cites] Hematol J. 2001;2(5):316-21 [11920267.001]
  • [Cites] Hematol J. 2004;5 Suppl 1:S38-49 [15079152.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1574-9 [10334546.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Drugs. 1997 Jun;53(6):1005-37 [9179529.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i58-9 [15888757.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):800-9 [11564066.001]
  • [Cites] Eur J Haematol. 1997 Aug;59(2):82-8 [9293855.001]
  • [Cites] Cancer Invest. 2002;20(7-8):904-13 [12449721.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):231-3 [10761763.001]
  • [Cites] Leukemia. 2004 May;18(5):1034-8 [14990978.001]
  • [Cites] Drugs. 2003;63(21):2317-23 [14524733.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1422-32 [16219580.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):754-61 [15009063.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i56-7 [15888756.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2042-9 [15372472.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4351-7 [12393618.001]
  • [Cites] Leukemia. 2007 May;21(5):1044-9 [17344917.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2412-20 [16649223.001]
  • [Cites] Value Health. 2003 Mar-Apr;6(2):167-74 [12641867.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):861-5 [10997815.001]
  • [Cites] Clin Lymphoma. 2002 Mar;2(4):229-37 [11970762.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2654-61 [15159414.001]
  • [Cites] Leuk Lymphoma. 2004 Jun;45(6):1141-7 [15359993.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4649-54 [12488409.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i60-1 [15888758.001]
  • [Cites] Drugs. 2006;66(6):791-820 [16706552.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1590-6 [16575010.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1 Suppl 1):S4-10 [15786020.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):466-72 [15695500.001]
  • [Cites] Clin Pharmacokinet. 2002;41(2):93-103 [11888330.001]
  • [Cites] Cancer. 2004 May 15;100(10):2181-9 [15139062.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1546-50 [17082012.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):174-80 [16330664.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):773-9 [10673518.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1191-7 [10586336.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):121-8 [17503433.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Mar;4(3):258-310 [16507273.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1996-2003 [12743154.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Blood. 2000 Jul 1;96(1):71-5 [10891432.001]
  • (PMID = 17661532.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 55
  •  go-up   go-down


54. Seto M: Genomic profiles in B cell lymphoma. Int J Hematol; 2010 Sep;92(2):238-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiles in B cell lymphoma.
  • Chromosome translocations found in B cell lymphomas generate typical genome profiles that are characteristic of each disease entity.
  • The mechanisms of lymphomagenesis have been investigated with respect to the involvement of deregulated genes in tumor development, as characterized by the promotion of cell proliferation and the blockage of cell differentiation and anti-apoptosis.
  • New technology such as array CGH and expression profiling introduced as a result of the human genome project introduced a new paradigm from which to understand the molecular mechanisms of lymphoma development.
  • Analyses with this new technology revealed that genome profiles of disease entities are characteristic and differ from disease to disease, although the genome profile of each patient with the same disease entity varies significantly given the recurrent genetic alterations frequently found.
  • Based on these findings, the future prospect and direction of lymphoma research will be discussed.
  • [MeSH-major] Lymphoma, B-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Science. 1983 Nov 18;222(4625):765-71 [6356357.001]
  • [Cites] Blood. 2009 Sep 17;114(12 ):2467-75 [19608751.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):1-7 [17886247.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):918-26 [7961120.001]
  • [Cites] Nature. 1988 Nov 17;336(6196):259-61 [2848196.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Leukemia. 2001 Jan;15(1):148-56 [11243383.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):47-56 [946170.001]
  • [Cites] Cell. 1984 Jan;36(1):93-9 [6319012.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Aug;46(8):776-83 [17492759.001]
  • [Cites] Haematologica. 2009 Jan;94(1):61-9 [19029149.001]
  • [Cites] Immunity. 2003 Nov;19(5):749-58 [14614861.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4148-52 [8364907.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(12):4589-93 [2543982.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Nature. 1991 Jan 17;349(6306):254-6 [1987477.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):247-55 [16049916.001]
  • [Cites] Nature. 1989 Nov 9;342(6246):195-8 [2478890.001]
  • [Cites] Cancer Res. 1979 Aug;39(8):3119-28 [582296.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5785-94 [10523859.001]
  • [Cites] Int J Cancer. 1978 Jul 15;22(1):14-21 [355152.001]
  • [Cites] J Clin Invest. 1987 Nov;80(5):1512-5 [3500184.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):704-10 [15471554.001]
  • [Cites] Nat Med. 2008 Feb;14(2):144-53 [18223655.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Jpn J Cancer Res. 1995 Sep;86(9):890-8 [7591969.001]
  • [Cites] J Cell Biol. 2009 Nov 2;187(3):429-42 [19948485.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1226-31 [8049438.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):30-8 [19118030.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1401-6 [1535701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1076-81 [18948948.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1770-7 [15886317.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12 ):1348-58 [17115033.001]
  • [Cites] Blood. 2001 Jul 15;98(2):486-8 [11435322.001]
  • [Cites] Nature. 1983 Nov 17-23;306(5940):239-42 [6316147.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1348-58 [15608680.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19012-9 [11262391.001]
  • [Cites] Blood. 1995 May 1;85(9):2528-36 [7727781.001]
  • [Cites] Cancer Sci. 2010 Mar;101(3):573-8 [20070305.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Nature. 1991 Apr 11;350(6318):512-5 [1826542.001]
  • [Cites] Cell. 2001 Jan 12;104(1):33-42 [11163238.001]
  • [Cites] EMBO J. 1988 Jan;7(1):123-31 [2834197.001]
  • (PMID = 20799004.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  •  go-up   go-down


55. Hashimoto M, Umekita N, Noda K: Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report. World J Gastroenterol; 2008 Jul 7;14(25):4093-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report.
  • Non-Hodgkin lymphoma is a rare cause of biliary obstruction.
  • To the best of our knowledge, non-Hodgkin lymphoma in the peripancreatic region causing obstructive jaundice with simultaneous portal vein (PV) invasion has not yet been reported.
  • We present a 50-year-old patient with obstructive jaundice whose extrahepatic portal vein was obstructed by the invasion of a peripancreatic non-Hodgkin lymphoma.
  • The patient denied any other symptoms such as recurrent fever, night sweat and loss of body weight.
  • The pathologic diagnosis was diffuse large B-cell type non-Hodgkin lymphoma and the patient was transferred to the Department of Hematology and Oncology for chemotherapy.
  • [MeSH-major] Jaundice, Obstructive / etiology. Lymphoma, Large B-Cell, Diffuse / pathology. Portal Vein / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1188-94 [10811326.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):43-9 [11466812.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Surg Today. 2003;33(1):72-4 [12560914.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2323-32 [17406815.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 May 1;71(9):2813-6 [7682150.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):485-8 [9764999.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):610-1 [15812422.001]
  • [Cites] J Gastrointest Surg. 2007 Jul;11(7):813-9 [17440790.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):503-7 [1323924.001]
  • (PMID = 18609698.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725353
  •  go-up   go-down


56. Nanjangud G, Rao PH, Teruya-Feldstein J, Donnelly G, Qin J, Mehra S, Jhanwar SC, Zelenetz AD, Chaganti RS: Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Cytogenet Genome Res; 2007;118(2-4):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression.
  • In addition to the known recurring translocations, t(14;18)(q32;q21) [70%], t(3;14)(q27;q32) [10%], t(1;14)(q21;q32) [5%] and t(8;14)(q24;q32) [2%] and their variants, 125 non-IG gene translocations were identified of which four were recurrent within this series.
  • This study also indicates that in addition to gains and losses, non-IG gene translocations involving 1p11-p13, 1p36, 1q11-q21, 8q24, 9p13, and 17q11-q21 play an important role in the histologic progression of FL with t(14;18)(q32;q21) and t(3q27).
  • [MeSH-major] Chromosomal Instability. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Lymphoma, Follicular / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000388.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA34775
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


57. Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer K, Huntsman D, Lam WL, Banerjee D: Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines. Mol Cancer; 2008;7:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines.
  • BACKGROUND: Hodgkin lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL), are forms of malignant lymphoma defined by unique morphologic, immunophenotypic, genotypic, and clinical characteristics, but both overexpress CD30.
  • We used sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization to screen HL-derived cell lines (KMH2 and L428) and ALCL cell lines (DEL and SR-786) in order to identify disease-associated gene copy number gains and losses.
  • RESULTS: Significant copy number gains and losses were observed on several chromosomes in all four cell lines.
  • Of the recurrent minimally altered regions identified, 11 (55%) were within previously published regions of chromosomal alterations in HL and ALCL cell lines while 9 (45%) were novel alterations not previously reported.
  • HL cell lines L428 and KMH2 shared gains in chromosome cytobands 2q23.1-q24.2, 7q32.2-q36.3, 9p21.3-p13.3, 12q13.13-q14.1, and losses in 13q12.13-q12.3, and 18q21.32-q23.
  • ALCL cell lines SR-786 and DEL, showed gains in cytobands 5p15.32-p14.3, 20p12.3-q13.11, and 20q13.2-q13.32.
  • Both pairs of HL and ALCL cell lines showed losses in 18q21.32-18q23.
  • CONCLUSION: This study is considered to be the first one describing HL and ALCL cell line genomes at sub-megabase resolution.
  • FISH was used to confirm the amplification of all three isoforms of the trypsin gene (PRSS1/PRSS2/PRSS3) in KMH2 and L428 (HL) and DEL (ALCL) cell lines.
  • These are novel findings that have not been previously reported in the lymphoma literature, and opens up an entirely new area of research that has not been previously associated with lymphoma biology.
  • [MeSH-major] Chromosome Aberrations. Gene Expression Profiling. Hodgkin Disease / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Nucleic Acid Hybridization
  • [MeSH-minor] Cell Line, Tumor. Gene Dosage. Humans. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence


58. Shen RR, Ferguson DO, Renard M, Hoyer KK, Kim U, Hao X, Alt FW, Roeder RG, Morse HC 3rd, Teitell MA: Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. Blood; 2006 Sep 15;108(6):1991-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.
  • TCL1, a proto-oncogene first recognized for its role in T-cell transformation, also induces GC B-cell malignancies when dysregulated in pEmu-B29-TCL1 transgenic (TCL1-tg) mice.
  • Clonal B-cell lymphomas develop from polyclonal populations with latencies of 4 months or more, suggesting that secondary genetic events are required for full transformation.
  • We report that compared with wild-type (WT) cells, B cells from TCL1-tg mice activated in a manner resembling a T-dependent GC reaction show enhanced resistance to FAS-mediated apoptosis with CD40 stimulation, independent of a B-cell antigen receptor (BCR) rescue signal.
  • These GC-related enhancements in survival and Aicda expression could underlie B-cell transformation.
  • Supporting this notion, no B-cell lymphomas developed for 20 months when TCL1-tg mice were crossed onto an Oct coactivator from B cell (OCA-B)-deficient background to yield mice incapable of forming GCs.
  • Spectral karyotype analyses showed that GC lymphomas from TCL1-tg mice exhibit recurrent chromosome translocations and trisomy 15, with corresponding MYC overexpression.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):542-7 [8849728.001]
  • [Cites] Cell Immunol. 1996 Oct 10;173(1):149-54 [8871610.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4782-91 [9234734.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):1783-93 [9257841.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):4834-9 [9366408.001]
  • [Cites] Blood. 1998 Jan 15;91(2):603-7 [9427715.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3885-9 [9520462.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jun;103(2):110-6 [9614908.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18470-6 [10373455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9809-14 [10449776.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3318-25 [15304391.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1385-96 [15867091.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):864-73 [16002684.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):640-8 [16056259.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] Am J Clin Pathol. 2005 Oct;124(4):569-75 [16146820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13242-7 [16141332.001]
  • [Cites] Mol Immunol. 2006 Feb;43(6):529-41 [16005067.001]
  • [Cites] Nature. 2006 Mar 2;440(7080):105-9 [16400328.001]
  • [Cites] Mol Cell Biol. 2002 Dec;22(23):8320-31 [12417733.001]
  • [Cites] Eur J Immunol. 2000 Jan;30(1):155-63 [10602037.001]
  • [Cites] Immunity. 1999 Dec;11(6):763-70 [10626898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3028-33 [10716693.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2095-100 [10786666.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Cell Res. 2000 Dec;10(4):245-66 [11191348.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1531-9 [11238890.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):555-64 [11304575.001]
  • [Cites] Science. 1987 Nov 27;238(4831):1272-5 [3685977.001]
  • [Cites] J Exp Med. 2003 Mar 3;197(5):657-67 [12615906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2639-44 [12604779.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Blood. 2003 May 1;101(9):3574-80 [12511417.001]
  • [Cites] J Exp Med. 2003 May 5;197(9):1173-81 [12732658.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19286-91 [12637527.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3894-8 [12873980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9974-9 [12909717.001]
  • [Cites] Apoptosis. 2003 Oct;8(5):451-60 [12975576.001]
  • [Cites] Trends Immunol. 2003 Oct;24(10):546-53 [14552839.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):212-20 [14713953.001]
  • [Cites] Int Immunol. 2004 Mar;16(3):395-404 [14978013.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2276-83 [14630790.001]
  • [Cites] Leukemia. 2004 Apr;18(4):826-31 [14990977.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35890-902 [15169787.001]
  • [Cites] Cell. 2004 Aug 20;118(4):431-8 [15315756.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1117-23 [15489857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12530-4 [7809072.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):163-5 [7533263.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1694-9 [7564512.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5638-43 [11607815.001]
  • [Cites] J Immunol. 2002 Apr 1;168(7):3369-75 [11907094.001]
  • [Cites] Biochemistry. 2002 May 21;41(20):6376-82 [12009899.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Trends Biochem Sci. 2002 Sep;27(9):462-7 [12217521.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):253-5 [12398888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14392-7 [12381789.001]
  • [Cites] Nature. 1980 Mar 27;284(5754):364-6 [7360273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nature. 1984 Jun 14-20;309(5969):592-7 [6547209.001]
  • (PMID = 16728701.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI 07126; United States / NCI NIH HHS / CA / CA 92625; United States / NCI NIH HHS / CA / CA 113872; United States / NCI NIH HHS / CA / CA 109901; United States / NCI NIH HHS / CA / CA 90571; United States / NCI NIH HHS / CA / CA 107300
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Tcl1 protein, mouse; 0 / Tumor Necrosis Factors; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC1895536
  •  go-up   go-down


59. Haque S, van Kirk R: Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8. Indian J Med Paediatr Oncol; 2009 Apr;30(2):76-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8.
  • BACKGROUND: The relationship between Hodgkin's lymphoma (HL) and plasma cell-type Castleman's disease (PCD) has been well documented.
  • It predisposes patients to a much higher risk of other malignancies, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • Patient 2 was first diagnosed with classic HL and 2 years later returned with enlarged lymph nodes clinically suspected to be recurrent HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Mar;18(3):249-53 [1675190.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):129-38 [1632458.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2923-30 [1954381.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):270-4 [8135630.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):833-9 [8375854.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):91-6 [8554455.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] Head Neck. 2001 Feb;23(2):166-9 [11303634.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):790-1 [11577129.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] Cancer. 1956 Jul-Aug;9(4):822-30 [13356266.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):91-100 [12502931.001]
  • [Cites] Histopathology. 2006 Feb;48(3):317-9 [16430484.001]
  • (PMID = 20596307.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885879
  • [Keywords] NOTNLM ; Castleman's disease / HHV-8 / Hodgkin's lymphoma / plasma cell variant of Castleman's disease
  •  go-up   go-down


60. Martirosyan A, Clendening JW, Goard CA, Penn LZ: Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer; 2010 Mar 18;10:103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The effect of lovastatin on ovarian cancer cell lines was evaluated alone and in combination with cisplatin and doxorubicin using several assays (MTT, TUNEL, fixed PI, PARP cleavage) and synergy determined by evaluating the combination index.
  • RESULTS: We demonstrate that lovastatin induces apoptosis of ovarian cancer cells in a p53-independent manner and synergizes with doxorubicin, a chemotherapeutic agent used to treat recurrent cases of ovarian cancer.
  • Lovastatin drives ovarian tumor cell death by two mechanisms: first, by blocking HMG-CoA reductase activity, and second, by sensitizing multi-drug resistant cells to doxorubicin by a novel mevalonate-independent mechanism.
  • This inhibition of drug transport, likely through inhibition of P-glycoprotein, potentiates both DNA damage and tumor cell apoptosis.
  • Moreover, we also show lovastatin synergizes with doxorubicin, an agent administered for recurrent disease.


61. Chang HH, Lu MY, Jou ST, Lin KH, Tien HF, Lin DT: Cytogenetics in childhood acute lymphoblastic leukemia in Taiwan: a single-institutional experience. Pediatr Hematol Oncol; 2006 Sep;23(6):495-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the patients with abnormal karyotypes, recurrent structural abnormalities were determined in 31 (50%) cases, with the most frequent t(9;22).
  • [MeSH-major] Chromosome Aberrations / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


62. Coleman M, Kostakoglu L: Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments? Cancer; 2006 Oct 1;107(7):1425-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hodgkin disease (HD) and diffuse large cell lymphoma (LCL) fit in this model well.
  • However, a subset of patients is either refractory to first-line treatment or develops recurrent disease after an initial remission.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16933331.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


63. Verma S, Frambach GE, Seilstad KH, Nuovo G, Porcu P, Magro CM: Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol; 2005 Aug;32(7):474-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin.
  • BACKGROUND: Epstein-Barr virus (EBV) has been implicated in B-cell lymphoma associated with iatrogenic immune dysregulation, primarily in the context of extracutaneous lymphoma.
  • METHODS: We describe six patients, five transplant recipients receiving cyclosporine and one patient with rheumatoid arthritis receiving methotrexate, who developed cutaneous presentations of EBV-associated B-cell lymphoma.
  • RESULTS: The cases comprised plasmablastic lymphoma (one case), plasmacytic marginal zone lymphoma (two cases), and diffuse large B-cell lymphoma (three cases).
  • Recurrent disease developed in two, with one patient succumbing to multiorgan dissemination.
  • CONCLUSIONS: EBV-associated cutaneous B-cell lymphoma is characterized by a long interval between the initiation of immunosuppression and the development of lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Immunocompromised Host. Lymphoma, B-Cell / immunology. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008691.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Messenger; 0 / RNA, Viral; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


64. Humphries W, Wei J, Sampson JH, Heimberger AB: The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am; 2010 Jan;21(1):125-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article discuss the role and prognostic significance of Tregs within glioma patients and delineates potential approaches for their inhibition that can be used alone or in combination with other immune therapeutics in clinical trials and in the clinical settings of recurrent or residual disease.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):309-16 [8877724.001]
  • [Cites] Blood. 1997 Jan 15;89(2):403-10 [9002941.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4734-40 [9144487.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4036-41 [9307290.001]
  • [Cites] J Immunol. 1997 Nov 1;159(9):4415-25 [9379040.001]
  • [Cites] Neurosurgery. 1997 Dec;41(6):1365-72; discussion 1372-3 [9402588.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1369-77 [9570556.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):525-37 [9711915.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2473-81 [9796980.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):279-88 [9892610.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 [10500201.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Hum Immunol. 2005 Mar;66(3):222-30 [15784460.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1591-602 [15883172.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jul;54(7):663-70 [15918076.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):992-7 [15856470.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1380-4 [16123302.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):253-7 [12658273.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7 [12682289.001]
  • [Cites] Transplantation. 2003 May 15;75(9 Suppl):8S-12S [12819483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4516-20 [12907625.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1206-12 [14578884.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6323-7 [14662827.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2158-67 [17404100.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):95-105 [17315190.001]
  • [Cites] Clin Genitourin Cancer. 2007 Jun;5(5):347-50 [17645835.001]
  • [Cites] Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii87-90 [17934104.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):98-103 [18079360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 [18287062.001]
  • [Cites] Immunol Rev. 2008 Apr;222:70-100 [18363995.001]
  • [Cites] J Immunol. 2008 Jul 15;181(2):1025-33 [18606654.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5166-72 [18698034.001]
  • [Cites] Immunology. 1971 Dec;21(6):903-14 [4943147.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2135-41 [6446379.001]
  • [Cites] Clin Exp Immunol. 1980 Feb;39(2):395-402 [6966992.001]
  • [Cites] J Immunol. 1980 Aug;125(2):711-4 [6156213.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4352-9 [15383564.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4095-102 [15353540.001]
  • [Cites] J Neurosurg. 1988 Mar;68(3):438-48 [3257792.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1858-67 [2230873.001]
  • [Cites] Immunol Today. 1993 Nov;14(11):523-5 [8274193.001]
  • [Cites] Science. 1994 Aug 26;265(5176):1237-40 [7520605.001]
  • [Cites] Immunology. 1994 Jul;82(3):365-9 [7959869.001]
  • [Cites] Immunity. 1994 Aug;1(5):405-13 [7882171.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] J Immunol. 1996 Jan 1;156(1):208-17 [8598464.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):387-96 [8760792.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4180-3 [16177055.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] J Immunother. 2005 Nov-Dec;28(6):582-92 [16224276.001]
  • [Cites] J Immunother. 2005 Nov-Dec;28(6):593-8 [16224277.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1005-16 [16283570.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1314-21 [16288283.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1219-27 [16244650.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1582-7 [16424187.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2722-9 [16493027.001]
  • [Cites] Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6 [16516670.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Immunity. 1999 Oct;11(4):483-93 [10549630.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3340-8 [10552943.001]
  • [Cites] Leukemia. 2000 Jan;14(1):129-35 [10637488.001]
  • [Cites] J Neuroimmunol. 1999 Dec;100(1-2):216-32 [10695732.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1622-36 [10764422.001]
  • [Cites] Immunity. 2000 Apr;12(4):431-40 [10795741.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2209-18 [10873070.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] J Immunol. 2000 Sep 15;165(6):3105-10 [10975823.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1105-13 [11034600.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1285-94 [11390435.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1303-10 [11390437.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]
  • [Cites] Immunol Rev. 2001 Aug;182:207-14 [11722636.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5267-72 [12234995.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Int Immunol. 2002 Dec;14(12):1397-406 [12456587.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Cancer Res. 1981 Jun;41(6):2163-7 [7016310.001]
  • [Cites] J Exp Med. 1982 Apr 1;155(4):1063-74 [6460831.001]
  • [Cites] J Immunol. 1984 Apr;132(4):1837-44 [6607949.001]
  • [Cites] J Exp Med. 1987 Jan 1;165(1):146-56 [2432148.001]
  • [Cites] Nature. 1987 Jul 16-22;328(6127):267-70 [3496540.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):874-9 [2824719.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):1021-31 [16606674.001]
  • [Cites] Blood. 2006 May 15;107(10):3925-32 [16418326.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):234-43 [16723631.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):261-79 [16775224.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305 [16857805.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1571-9 [16645171.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):430-7 [16961139.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):144-53 [16959895.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Cancer Immunol Immunother. 2007 May;56(5):641-8 [16960692.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1810-5 [17363537.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5759-68 [18794085.001]
  • [Cites] J Immunol. 2008 Nov 15;181(10):6720-9 [18981089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jul;58(7):1023-32 [19002459.001]
  • [Cites] Int Immunol. 2000 Feb;12(2):177-85 [10653853.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8408-13 [14679003.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):610-6 [14726505.001]
  • [Cites] Cell Death Differ. 2004 Apr;11(4):448-57 [14713959.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4676-80 [15067041.001]
  • [Cites] Microbes Infect. 2004 Jul;6(8):745-51 [15207821.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1725-30 [15210748.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • (PMID = 19944972.001).
  • [ISSN] 1558-1349
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120813; United States / NCI NIH HHS / CA / R01 CA120813-03; United States / PHS HHS / / A177225-01; United States / NCI NIH HHS / CA / CA120813-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 124
  • [Other-IDs] NLM/ NIHMS142642; NLM/ PMC2786818
  •  go-up   go-down


65. Yin CC, Medeiros LJ, Bueso-Ramos CE: Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification. Int J Lab Hematol; 2010 Oct;32(5):461-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The subgroup 'acute myeloid leukemia (AML) with recurrent genetic abnormalities' has been expanded to include more molecular genetic aberrations.


66. Conrad AL, Go RS: Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma. Eur J Haematol; 2009 Dec 1;83(6):603-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
  • Prophylactic radiation to the contralateral uninvolved testicle has become a standard practice in the treatment of primary testicular lymphoma.
  • We describe a patient with primary testicular diffuse large B-cell lymphoma, who developed recurrent disease in the contralateral testicle despite receiving prophylactic testicular radiation, central nervous system prophylaxis, and anthracycline-based chemo-immunotherapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Radiotherapy, Adjuvant. Testicular Neoplasms / secondary
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Testis Barrier. Bone Marrow / pathology. Carboplatin / administration & dosage. Carboplatin / pharmacokinetics. Central Nervous System Neoplasms / prevention & control. Cyclophosphamide / administration & dosage. Cyclophosphamide / pharmacokinetics. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Etoposide / administration & dosage. Etoposide / pharmacokinetics. Fatal Outcome. Hematopoietic Stem Cell Transplantation. Humans. Ifosfamide / administration & dosage. Ifosfamide / pharmacokinetics. Injections, Spinal. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Orchiectomy. Prednisone / administration & dosage. Prednisone / pharmacokinetics. Remission Induction. Rituximab. Salvage Therapy. Transplantation Conditioning. Treatment Failure. Vincristine / administration & dosage. Vincristine / pharmacokinetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682312.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 13
  •  go-up   go-down


67. Varghese BT: B cell lymphoma masquerading as recurrent tonsillitis with necrotising lymphadenitis (Kikuchi's disease). J Indian Med Assoc; 2006 Mar;104(3):154
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell lymphoma masquerading as recurrent tonsillitis with necrotising lymphadenitis (Kikuchi's disease).
  • [MeSH-major] Histiocytic Necrotizing Lymphadenitis / diagnosis. Lymphadenitis / diagnosis. Lymphoma, B-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Indian Med Assoc. 2004 Jun;102(6):330 [15636044.001]
  • (PMID = 16910343.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] India
  •  go-up   go-down


68. Hamamoto K, Oriuchi N, Kanazawa T, Higuchi T, Endo K: Mesial temporal sclerosis associated with methotrexate-induced leukoencephalopathy. Pediatr Neurol; 2009 Apr;40(4):306-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present clinical records and neuroimaging results of a 13-year-old patient with acute lymphoblastic leukemia who developed recurrent partial seizures after an episode of leukoencephalopathy thought to be caused by methotrexate.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Positron-Emission Tomography. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sclerosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302946.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


69. Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R, Ayukawa H, Kumagai MA, Horibe K, Tsurusawa M: Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol; 2006 Mar;132(5):594-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan.
  • This report presents a retrospective study of 26 Japanese children with recurrent anaplastic large cell lymphoma.
  • The patients who received allogeneic haematopoietic stem cell transplantation during second CR showed a superior outcome to other patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Japan. Male. Neoplasm Recurrence, Local / mortality. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445832.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


70. Crow J, Youens K, Michalowski S, Perrine G, Emhart C, Johnson F, Gerling A, Kurtzberg J, Goodman BK, Sebastian S, Rehder CW, Datto MB: Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis. J Mol Diagn; 2010 Jul;12(4):530-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis.
  • Donor cell neoplasms are rare complications of treatment regimens that involve stem cell transplantation for hematological malignancies, myelodysplastic processes, or certain genetic or metabolic disorders.
  • We report a case of donor cell leukemia in a pediatric patient with a history of acute myeloid leukemia that manifested as recurrent AML FAB type M5 fourteen months after umbilical cord blood transplantation.
  • Although there was some immunophenotypic drift from the patient's original AML and their posttransplant presentation, the initial pathological impression was of recurrent disease.
  • This case highlights the need for close coordination between all aspects of clinical testing for the transplant patient, including molecular engraftment studies, when distinguishing the very common complication of recurrent disease from the exceedingly rare complication of donor cell leukemia.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute / pathology. Neoplasm Transplantation / adverse effects. Tissue Donors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1862-70 [7495309.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):294-8 [16044441.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2101-16 [16136167.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4377-80 [16118319.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):184-94 [16443516.001]
  • [Cites] Am J Surg Pathol. 2006 Mar;30(3):328-36 [16538052.001]
  • [Cites] Leukemia. 2006 Apr;20(4):744-5 [16437136.001]
  • [Cites] Am J Hematol. 2000 Jan;63(1):46-53 [10602169.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):288-94 [16645218.001]
  • [Cites] Eur J Haematol. 2006 Sep;77(3):259-63 [16923113.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1633-4 [16791267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14483-8 [16980411.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1952-5 [17065011.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):25-38 [17325845.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jul;7(7):475-9 [17875238.001]
  • [Cites] Int J Hematol. 2007 Aug;86(2):192-5 [17875537.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(1):91-2 [17982506.001]
  • [Cites] Cytotherapy. 2007;9(8):727-8 [17917889.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4318-27 [18723429.001]
  • [Cites] Bone Marrow Transplant. 2009 Mar;43(5):429-31 [18978827.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2410-5 [18997171.001]
  • [Cites] Curr Protoc Hum Genet. 2009 Jul;Chapter 9:Unit 9.17 [19582766.001]
  • [Cites] J Pathol. 2009 Aug;218(4):478-86 [19391128.001]
  • [Cites] Bone Marrow Transplant. 2009 Nov;44(10):653-9 [19802021.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(7):395-9 [11529490.001]
  • [Cites] Clin Lab Haematol. 2001 Jun;23(3):173-9 [11553058.001]
  • [Cites] Forensic Sci Int. 2001 Dec 15;124(1):47-54 [11741760.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):230-2 [12411591.001]
  • [Cites] Bone Marrow Transplant. 2004 Jun;33(12):1253-6 [15146169.001]
  • [Cites] Leukemia. 1995 Jun;9(6):972-6 [7596187.001]
  • [Cites] Haematologica. 2005 Jul;90(7):969-75 [15996934.001]
  • (PMID = 20431036.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  • [Other-IDs] NLM/ PMC2893640
  •  go-up   go-down


71. Makino K, Nakamura H, Kudo M, Takeshima H, Kuratsu J: Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):229-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
  • An 80-year-old woman presented with primary central nervous system (CNS) lymphoma manifesting as progressive disorientation and loss of activity.
  • Temozolomide may be effective against relapsed primary CNS lymphoma without causing neurotoxicity in the elderly.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527051.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


72. Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E: Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol; 2007 Aug;14(4):154-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article, we discuss the biologic and clinical rationales that have recently led the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group to initiate four phase ii trials testing this agent in the following four different tumour types: relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1994 Feb;21(1):54-62 [8310310.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):792-5 [8622025.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):500-2 [9155539.001]
  • [Cites] Br J Cancer. 1997;76(9):1221-7 [9365173.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):8-12 [10431840.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):777-82 [10717248.001]
  • [Cites] Blood. 2000 Jul 1;96(1):282-7 [10891463.001]
  • [Cites] Exp Hematol. 2000 Sep;28(9):993-1000 [11008011.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):167-72 [11191056.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):213-5 [11354055.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3658-61 [11369666.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4341-4 [11389057.001]
  • [Cites] Med Oncol. 2001;18(4):269-75 [11918453.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22 [12040530.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):469-75 [12051876.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93 [12359857.001]
  • [Cites] Mol Pathol. 2002 Dec;55(6):348-59 [12456770.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):377-82 [12538491.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Adv Exp Med Biol. 2003;522:83-97 [12674213.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):673-9 [13130314.001]
  • [Cites] Blood. 1992 Oct 15;80(8):2142-8 [1356515.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):107-18 [15168728.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2893-902 [15238424.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):489-501 [15516973.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):101-11 [15652753.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):902-5 [15721449.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4626-33 [15911865.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Dec;315(3):971-9 [16002463.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1345-51 [16109613.001]
  • [Cites] Curr Opin Oncol. 2005 Nov;17(6):611-6 [16224242.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii13-viii19 [16239232.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):389-93 [1999708.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1079-85 [3894589.001]
  • [Cites] Radiother Oncol. 1995 May;35(2):107-17 [7569018.001]
  • [Cites] Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805-7 [8456884.001]
  • (PMID = 17710208.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1948864
  •  go-up   go-down


73. Lu PP, Meng ZY, Zhou MX, Wang MW, Dou GF: [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec;14(6):1258-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
  • Its expression is restricted to the B cell lineage and a vast majority of B cell NHLs.
  • CD22 plays a key role in B cell development, survival, and function.
  • Preclinical test with anti-CD22 antibodies indicates that a single, conjugated or radiolabeled agent has shown preliminary antitumor activity in patients with recurrent and heavily pretreated NHL.
  • Thus, anti-CD22 antibodies are theoretically good candidates alone and in combination with other drugs in the treatment of B cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204206.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Cd22 protein, mouse; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab
  • [Number-of-references] 18
  •  go-up   go-down


74. Ianotto JC, Tempescul A, Eveillard JR, André N, Morel F, Quintin-Roué I, Berthou C: Acute dyspnoea and single tracheal localisation of mantle cell lymphoma. J Hematol Oncol; 2010;3:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute dyspnoea and single tracheal localisation of mantle cell lymphoma.
  • BACKGROUND: Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis.
  • RESULTS: We report here the first case of a unique tracheal localisation of mantle cell lymphoma at presentation of the disease.
  • The presence of classical t(11;14)(q13;q32) confirmed the diagnosis of mantle cell lymphoma by eliminating MALT or cancer localisation.
  • CONCLUSION: This case illustrates the necessity to ensure the diagnosis of mucosal lymphoma versus MCL since these diseases need different treatment regimens and prognoses.
  • [MeSH-major] Dyspnea / etiology. Lymphoma, Mantle-Cell / complications. Tracheal Neoplasms / complications


75. Terui Y, Sakurai T, Mishima Y, Mishima Y, Sugimura N, Sasaoka C, Kojima K, Yokoyama M, Mizunuma N, Takahashi S, Ito Y, Hatake K: Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci; 2006 Jan;97(1):72-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
  • Recently, anti-CD20 (rituximab) and anti-Her2/neu (trastuzumab) antibodies have been developed and applied to the treatment of malignant lymphoma and breast cancer, respectively.
  • However, bulky lymphoma is known to be resistant to rituximab therapy, and this needs to be overcome.
  • Fresh lymphoma cells were collected from 30 patients with non-Hodgkin's lymphoma, the expression of CD20 and CD55 was examined by flow cytometry, and complement-dependent cytotoxicity (CDC) assays were carried out.
  • One complement-inhibitory protein, CD55, contributed to bulky lymphoma-related resistance to CDC with rituximab.
  • To overcome the resistance to rituximab by high expression of CD55 in bulky lymphoma masses, small interfering RNA (siRNA) was designed from the DNA sequence corresponding to nucleic acids 1-380 of the CD55 cDNA.
  • Introduction of this siRNA decreased CD55 expression in the breast cancer cell line SK-BR3 and in CD20-positive cells of patients with recurrent lymphoma; resistance to CDC was also inhibited.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD55 / metabolism. Complement System Proteins / drug effects. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Lymphoma / genetics. Lymphoma / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor. Humans. RNA Interference. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Rituximab

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2006; 97: 72-79).
  • (PMID = 16367924.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD55; 0 / RNA, Small Interfering; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


76. Harned TM, Gaynon P: Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep; 2008 Nov;10(6):453-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, most relapse patients do achieve a second complete remission, followed by therapeutic options including further chemotherapy and hematopoietic stem cell transplant.
  • The high likelihood of achieving a third remission may discourage participation in single-agent trials of new drugs, despite the critical need for novel agents with activity against resistant disease that may improve outcomes for recurrent ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Child. Clinical Trials as Topic. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Medical Oncology / methods. Prognosis. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 2005 Jun;39(6):1056-63 [15870141.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2826-32 [17099879.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2321-32 [9404710.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):369-70 [15902772.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):1-2 [17325839.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1043-50 [17640858.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2057-66 [17536015.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):233-9 [9473758.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):68-72 [9065722.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(2):133-9 [17994118.001]
  • [Cites] Leukemia. 2008 Feb;22(2):281-6 [18033318.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • (PMID = 18928659.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


77. Zhou Y, Ye H, Martin-Subero JI, Gesk S, Hamoudi R, Lu YJ, Wang R, Shipley J, Siebert R, Isaacson PG, Dogan A, Du MQ: The pattern of genomic gains in salivary gland MALT lymphomas. Haematologica; 2007 Jul;92(7):921-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent chromosomal changes were further verified by interphase fluorescence in situ hybridization (FISH).
  • Recurrent gains were found at 1p32-ter (42%), 9q33-34 (84%), 11q11-13 (42%), 17 (58%) and 18q21-22 (42%).
  • Among these, the recurrent gains at 9q34, 11q11-13 and 18q21 were nearly the exclusive gain of the corresponding chromosome.
  • INTERPRETATION AND CONCLUSIONS: Salivary gland MALT lymphomas show a conserved pattern of chromosomal gains, which appear to target genes positively modulating cell survival and proliferation.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, B-Cell, Marginal Zone / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Cell Proliferation. Cell Survival / genetics. Genome, Human. Humans. In Situ Hybridization

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606442.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


78. Schwindt H, Akasaka T, Zühlke-Jenisch R, Hans V, Schaller C, Klapper W, Dyer MJ, Siebert R, Deckert M: Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol; 2006 Aug;65(8):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination.
  • Primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphomas confined to the brain.
  • [MeSH-major] Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Immunoglobulin Class Switching / genetics. Lymphoma, B-Cell / genetics. Somatic Hypermutation, Immunoglobulin / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896311.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LPP protein, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


79. Reichard KK, Hall BK, Corn A, Foucar MK, Hozier J: Automated analysis of fluorescence in situ hybridization on fixed, paraffin-embedded whole tissue sections in B-cell lymphoma. Mod Pathol; 2006 Aug;19(8):1027-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated analysis of fluorescence in situ hybridization on fixed, paraffin-embedded whole tissue sections in B-cell lymphoma.
  • Certain recurrent cytogenetic abnormalities are diagnostic of a specific neoplasm and may portend prognosis.
  • Three probe sets were analyzed on archival specimens with a confirmed diagnosis of mantle cell lymphoma, follicular lymphoma or Burkitt lymphoma.
  • 100% of mantle cell lymphomas (7/7) were positive for t(11;14), 91% of follicular lymphomas (10/11) for t(14;18) and 100% of Burkitt lymphomas (9/9) for t(8;14).
  • Based on these results, automated analysis of fluorescence in situ hybridization on fixed tissues is accurate and valuable in the evaluation of B-cell lymphoma, and may provide pertinent diagnostic and prognostic information.
  • [MeSH-major] Image Processing, Computer-Assisted / methods. In Situ Hybridization, Fluorescence / methods. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Humans. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Paraffin Embedding. Prognosis. Tissue Fixation. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680153.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Tsuzuki S, Karnan S, Horibe K, Matsumoto K, Kato K, Inukai T, Goi K, Sugita K, Nakazawa S, Kasugai Y, Ueda R, Seto M: Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization. Cancer Sci; 2007 May;98(5):698-706
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a search for additional genetic events that could be linked to the development of leukemia, we applied a genome-wide array-comparative genomic hybridization technique to 24 TEL-AML1 leukemia samples and two cell lines.
  • Recurrent regions of chromosomal imbalance (>10% of cases) and representative involved genes were gain of chromosomes 10 (17%) and 21q (25%; RUNX1) and loss of 12p13.2 (87%; TEL), 9p21.3 (29%; p16INK4a/ARF), 9p13.2 (25%; PAX5), 12q21.3 (25%; BTG1), 3p21 (21%; LIMD1), 6q21 (17%; AIM1 and BLIMP1), 4q31.23 (17%; NR3C2), 11q22-q23 (13%;.
  • Enforced expression of TEL and to a lesser extent BTG1, both single genes known to be located in their respective minimum common region of loss, inhibited proliferation of the TEL-AML1 cell line Reh.
  • [MeSH-major] Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Cell Proliferation. Child. Child, Preschool. Chromosome Deletion. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Proteins / genetics. Nucleic Acid Hybridization / methods. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374122.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 146835-72-5 / BTG1 protein, human
  •  go-up   go-down


81. Padate BP, Keidan J: Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab. Clin Lab Haematol; 2006 Feb;28(1):69-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab.
  • A 75-year-old man, with a long history of recurrent lymphoplasmacytoid lymphoma, presented with diffuse large-cell lymphoma affecting adrenal glands and causing severe hypoadrenalism.
  • The lymphoma responded to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy.
  • Rituximab can cause prolonged B-cell deficiency.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Enterovirus Infections / etiology. Immunosuppression / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Meningoencephalitis / etiology

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430465.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulins, Intravenous; 0 / RNA, Viral; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Sevilla DW, Weeden EM, Alexander S, Murty VV, Alobeid B, Bhagat G: Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas. Virchows Arch; 2009 Oct;455(4):323-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas.
  • Different patterns of bone marrow (BM) infiltration by diffuse large B cell lymphomas (DLBCL) have been described.
  • We evaluated BM biopsies involved by large B cell lymphomas diagnosed at our institute over an 11-year period to assess the morphology, phenotype, cytogenetic abnormalities, and clinical features of cases associated with a nodular pattern.
  • No recurrent cytogenetic abnormalities were detected in either group.
  • [MeSH-major] Bone Marrow / pathology. Herpesvirus 4, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5124-32 [17785567.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):920-37 [16231177.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1163-72 [1694234.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1458-66 [12409722.001]
  • [Cites] J Clin Exp Hematop. 2006 Mar;46(1):1-4 [17058802.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):185-92 [18436998.001]
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1233-40 [11123421.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 15;132(2):125-32 [11850073.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):293-302 [12604885.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):745-50 [1401199.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1279-87 [8827036.001]
  • [Cites] Korean J Lab Med. 2007 Dec;27(6):383-7 [18160826.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):305-11 [8135186.001]
  • [Cites] Mech Ageing Dev. 2003 Apr;124(4):477-85 [12714256.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3083-8 [12115338.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1667-9 [16966281.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1085-91 [18429953.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):888-97 [6977408.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):893-7 [17573693.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2571-8 [17119113.001]
  • [Cites] Arch Pathol Lab Med. 2007 May;131(5):742-7 [17488159.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1532-44 [17495977.001]
  • [Cites] Eur J Haematol. 2004 Sep;73(3):149-55 [15287910.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Br J Haematol. 1988 Jun;69(2):229-37 [3291929.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Am J Hematol. 1996 May;52(1):21-8 [8638607.001]
  • [Cites] J Pathol. 1999 Jun;188(2):133-8 [10398155.001]
  • [Cites] Haematologica. 2006 Oct;91(10):1313-20 [17018379.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Nat Rev Immunol. 2009 Jan;9(1):57-62 [19104499.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • [Cites] Hematol Oncol Clin North Am. 1988 Dec;2(4):617-35 [3065322.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):163-6 [16441428.001]
  • [Cites] Neuropathology. 2008 Dec;28(6):640-4 [18410281.001]
  • [Cites] Am J Clin Pathol. 1997 Nov;108(5):570-8 [9353097.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):429-37 [11304562.001]
  • [Cites] Eur J Haematol. 2006 Jun;76(6):473-80 [16529599.001]
  • [Cites] Hematol Oncol. 2008 Dec;26(4):199-211 [18457340.001]
  • [Cites] Am J Transplant. 2008 May;8(5):1016-24 [18312608.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1549-57 [16327427.001]
  • (PMID = 19806362.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


83. Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, Murty VV, Bhagat G: Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol; 2007 Feb;38(2):315-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion.
  • Cytogenetic abnormalities in B-cell posttransplant lymphoproliferative disorders (PTLD) have not been well characterized.
  • We thus performed cytogenetic analysis of 28 cases of B-cell PTLD, 1 infectious mononucleosis (IM)-like lesion, 9 polymorphic PTLD, 17 monomorphic PTLD, and 1 classical Hodgkin lymphoma (HL), and correlated the karyotypic findings with the phenotype, Epstein-Barr virus infection status, and clinical outcome.
  • Recurrent chromosome breaks at 1q11-21 (n = 6, including 1 FFH), 14q32 (n = 3, including 1 FFH), 16p13 (n = 3), 11q23-24 (n = 2), and 8q24 (c-MYC) (n = 2); gains of chromosome 7 (n = 4), X (n = 3), 2 (n = 3), 12 (n = 2); and loss of chromosome 22 (n = 2, including 1 IM-like lesion) were identified.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134734.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Vega F, Medeiros LJ, Gaulard P: Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol; 2007 Jun;127(6):869-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic and other gammadelta T-cell lymphomas.
  • The 2005 Society for Hematopathology/European Association for Haematopathology Workshop session 11 was dedicated to hepatosplenic T-cell lymphoma (HSTCL).
  • HSTCL is a rare aggressive type of extranodal lymphoma characterized by hepatosplenomegaly, bone marrow involvement, and peripheral blood cytopenias.
  • The tumor cells have a nonactivated cytotoxic T-cell immunophenotype and frequently carry a recurrent cytogenetic abnormality, isochromosome 7q.
  • Most cases express the gammadelta T-cell receptor, but cases can have an alphabeta phenotype and are considered to be a variant of the disease.
  • Although HSTCL is the prototype peripheral T-cell lymphoma expressing the gammadelta T-cell receptor, non-HSTCL proliferations of gammadelta T cells can involve other extranodal sites, mainly skin and mucosa.
  • These gammadelta T-cell lymphomas display marked heterogeneity in clinical and histologic features.
  • In contrast with HSTCL, non-HSTCL gammadelta T-cell lymphomas frequently have an activated cytotoxic phenotype and most likely are not a single disease entity.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell, Peripheral / pathology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Splenic Neoplasms / pathology. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509984.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


85. Rahemtullah A, Longtine JA, Harris NL, Dorn M, Zembowicz A, Quintanilla-Fend L, Preffer FI, Ferry JA: CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol; 2008 Nov;32(11):1593-607
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature.
  • Rare cases of CD20+ T-cell lymphoma (TCL) have been reported, but the clinicopathologic spectrum of this disorder is not known.
  • Three cases fulfilled diagnostic criteria for clinicopathologically defined subtypes of TCL (2 mycosis fungoides; 1 enteropathy-type TCL), whereas 6 were peripheral TCL unspecified with variable cytomorphology, T-cell immunophenotype, and sites of involvement.
  • In 8 of 9 cases, a clonal T-cell population was identified by molecular genetic analysis.
  • Among 8 cases with clinical follow-up, 5 behaved aggressively with death from disease within 3 years of diagnosis in 4 cases (median survival: 11 mo, range: 1 to 35 mo), and recurrent disease at 10 months in 1 case; 1 patient died of an EBV+ B-cell lymphoma (BCL) 66 months after the original diagnosis; in the remaining 2 cases, patients were alive and undergoing treatment (follow-up: 4 and 18 mo).
  • When CD20 expression is present in TCL, it may be dimmer than that of normal B cells, suggesting neoplastic transformation of a normal CD20dim+ T-cell subset.
  • [MeSH-major] Antigens, CD20 / biosynthesis. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blotting, Southern. Combined Modality Therapy. Female. Flow Cytometry. Genes, T-Cell Receptor beta / genetics. Genes, T-Cell Receptor gamma / genetics. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Male. Phototherapy. Polymerase Chain Reaction. Radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753947.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


86. Pearce HL, Alice Miller M: The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul; 2005;45:229-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gemcitabine, a pyrimidine nucleoside that has a profound effect on DNA synthesis, has been approved for the treatment of pancreatic, non-small cell lung, bladder, and most recently, breast, and ovarian cancer.
  • Pemetrexed, given in combination with cisplatin, has been recently approved for the treatment of malignant pleural mesothelioma and as second-line treatment for non-small cell lung cancer.
  • Enzastaurin has shown promising single-agent activity in patients with relapsed diffuse large B-cell lymphoma and recurrent glioblastoma multiforme, and is an excellent candidate for combination with cytotoxic agents.

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143373.001).
  • [ISSN] 0065-2571
  • [Journal-full-title] Advances in enzyme regulation
  • [ISO-abbreviation] Adv. Enzyme Regul.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Indoles; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; UC96G28EQF / enzastaurin
  •  go-up   go-down


87. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T: Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer; 2010 Oct 1;116(19):4541-8